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Hippocampus has a central role 
in many functions related to 
memory. Hippocampal neurons are 
susceptible to various insults. The 
objective of the study was to assess 
the prevalence of hippocampal 
lesions in an unselected post-mortem 
cohort. Various lesions and their 
association with cardiovascular risk 
factors and epilepsy was examined. 
These studies increase our 
knowledge on hippocampal lesions 
and resulted in recommendations 
for the post-mortem assessment of 
hippocampus in aged subjects.
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ABSTRACT 
 
The hippocampus is highly suspectible to damage. The prevalence of hippocampal lesions 
has not previously been studied thoroughly in a large unselected post-mortem cohort. In 
particular, the terminology used for hippocampal lesions in neuropathology has not been 
clearly defined.  In the first part of the study, 1388 samples from an unselected post-mortem 
cohort were analyzed and a hippocampal lesion was detected in 251 cases (18%). Five 
different lesion types were defined and this classification was used in the following four 
studies.    
 In the first study, the prevalence of hippocampal infarcts was assessed in a large 
post-mortem cohort of 1,245 subjects. In addition, the prevalence of cardiovascular diseases 
and well known cardiovascular risk factors were examined in subjects with a hippocampal 
infarct and also in a control group.  The main finding was that the prevalence of hippocampal 
infarct was 12% and hippocampal infarcts were associated with gross cerebral infarcts, heart 
failure and the overall burden of cardiovascular disease assessed post-mortem.    
 Transactive response DNA binding protein 43 (TDP43) pathology is associated 
with numerous neurodegenerative diseases. The second study assessed the prevalence 
hippocampal TDP43 pathology in subjects with hippocampal lesions and correlated these 
findings to other neuropathological signs. The main outcome was that the prevalence of 
TDP43 protein in the hippocampus was relatively common in subjects with a hippocampal 
lesion; in particular subjects with AD, dementia with Lewy bodies (DLB), or both, were 
affected.   
 The reproducibility and reliability of the definitions devised in the initial part of 
this thesis project were evaluated in the third study. In an inter-rater study, four experienced 
neuropathologists assessed 260 specimens and classified them according to the definitions 
into five different types or as controls (i.e. without hippocampal pathology). Those cases with 
hippocampal infarcts were the most reproducible. The neurodegenerative cases displayed 
more variationIt was agreed that hippocampal lesions could be reliably assessed according 
to these definitions, but the use of immunohistochemical stains would be mandatory if one 
wished to identify the neurodegenerative lesions. In addition, recommendations on the use 
of the term “hippocampal sclerosis” were given.  
 For the fourth study, 30 subjects with hippocampal sclerosis who had been 
identified during the third study, were assessed in detail using post-mortem findings and 
patient records. The aim was to investigate whether hippocampal sclerosis in the elderly 
would be associated with epilepsy. In this group of subjects, neurodegenerative diseases 
were common and the clinicopathological spectrum was diverse. Five out of the 30 subjects 
had suffered from epilepsy at some point during their life.  
 
National Library of Medicine Classification: QZ 190, WL 314, WL 356, WL 358.5 Medical Subject Headings: 
Brain/pathology; Hippocampus/pathology; Infarction; Neurodegenerative Diseases; Alzheimer Disease; Lewy 
Body Disease; Sclerosis; DNA-Binding Proteins; Epilepsy; Cardiovascular Diseases; Epidemiology; 
Reproducibility of Results; Autopsy; Aged 
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TIIVISTELMÄ 
 
Hippokampuksen alue on herkkä vaurioitumaan erilaisten ärsykkeiden, kuten 
hapenpuutteen tai rappeuttavan aivosairauden vuoksi. Hippokampuksen muutosten 
esiintyvyydestä valikoimattomassa ruumiinavausaineistossa ei ole ollut riittävästi tietoa ja 
lisäksi neuropatologisessa tutkimisessa todettujen hippokampuksen muutosten 
terminologia ei ole ollut yksiselitteisesti määritelty. Tämän väitöskirjatyön tarkoituksena oli 
selvittää hippokampuksen muutosten esiintyvyyttä, arvioiden toistettavuutta sekä yhteyttä 
sydän- ja verisuonitauteihin, rappeuttaviin aivosairauksiin ja epilepsiaan laajassa 
ruumiinavausaineistossa (n=1388). Näistä 251 (18%) tapauksessa löytyi mikroskoopissa 
nähtävä muutos ja näiden perusteella kuvattiin viisi erilaista muutostyyppiä, jotka olivat 
perustana tämän väitöskirjatutkimuksen osatöille.  
 Ensimmäisessä osatyössä tutkittiin hippokampuksen infarktien esiintyvyyttä 
laajassa ruumiinavausaineistossa. Lisäksi selvitettiin sydän- ja verisuonisairauksien 
esiintyvyyttä sekä näiden yleisiä riskitekijöitä vainajilla, joilla esiintyi hippokampuksen 
infarkti verrattuna kontrolliryhmään. Keskeisin löydös tässä osatyössä oli se, että 
hippokampuksen infarkti esiintyi 12% tutkitusta 1,245 vainajasta ja nämä yhdistyivät 
merkitsevästi kookkaisiin aivoinfarkteihin, sydämen vajaatoimintaan ja ruumiinavauksessa 
todettuun sydän- ja verisuonisairauksien asteeseen.   
 Toisessa osatyössä tutkittiin useisiin rappeuttaviin aivosairauksiin liittyvän 
patologisen TDP-43 proteiinin esiintyvyyttä vainajilla, joilla esiintyi muutos 
hippokampuksessa. Tämän työn keskeinen löydös oli se, että näillä vainajille patologista 
TDP-43 proteiinia esiintyy verrattain yleisesti ja riski tähän on erityisen suuri niillä, joilla on 
Alzheimerin tauti tai Lewyn kappale-dementia, tai mahdollisesti näiden yhdistelmä.   
 Kolmannessa osatyössä selvitettiin tutkimuksen alkuvaiheessa määriteltyjen 
viiden muutostyypin arvioin toistettavuutta monikeskustutkimuksessa. Tässä työssä neljä 
kokenutta neuropatologia arvioi 260 näytettä laatimaamme ohjetta käyttäen. Arvio oli 
yhteneväisin niissä tapauksissa, joissa muutos oli tyypiltään infarkti. Hajonta oli runsaampaa 
tapauksissa, joissa esiintyi rappeuttaviin aivosairauksiin liittyviä muutoksia. Todettiin että 
hippokampuksen muutoksisille voidaan antaa luotettavasti toistettava arvio tekemämme 
ohjeen perusteella, mutta immunohistokemialliset värjäykset ovat välttämättömiä 
rappeuttaviin aivosairauksiin liittyvien muutosten toteamiseksi. Tässä osatyössä annettiin 
myös suositus termin ”hippokampaalinen skleroosi” käytöstä neuropatologisessa 
diagnostiikassa.      
 Neljänteen osatyöhön valittiin kolmannen osatyön perusteella 30 vainajaa, joilla 
esiintyi hippokampaalinen skleroosi ja työssä tutkittiin tarkemmin näiden kliinis-patologisia 
löydöksiä sekä potilaskertomuksia. Rappeuttavat aivosairaudet olivat tässä ryhmässä 
yleisiä. Löydökset vainajilla olivat hyvin monimuotoisia ja elinaikana epilepsiaa oli 
sairastanut viisi vainajaa tutkitusta kolmestakymmenestä.    
Luokitus: QZ 190, WL 314, WL 356, WL 358.5 Yleinen suomalainen asiasanasto: aivot; hippokampus; 
patologia; Alzheimerin tauti; Lewyn kappale –dementia; epilepsia; sydän- ja verisuonitaudit; epidemiologia; 
toistettavuus; reliabiliteetti; ruumiinavaus; ikääntyneet  
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1 Introduction  
The hippocampal formation is an evolutionary ancient and important part of the brain. It is 
an archicortical structure located in the mesial temporal lobe extending into the floor of the 
lateral ventricle and it is part of the limbic system. Neuroanatomically it is made up by the 
dentate gyrus, the cornu ammonis (CA) and the subiculum (Amaral, Lavenex 2007). The 
hippocampus has a central role in many complex functions related to memory such that 
when its function is altered in diseases, this is associated with memory disturbances and 
cognitive impairment. Hippocampal neurons are particularly susceptible to ischemia and 
other insults. One generally accepted reason for the vulneratiblity of hippocampal neurones 
is their high concentration of glutamate receptors, which when activated excessively, cause 
a condition called excitotoxic cell death  (Olney, Collins & Sloviter 1986). In addition to 
hypoxic/ischemic insults, other hippocampal lesions, such as neuronal loss, gliosis, 
intracellular accumulation of misfolded proteins such as hyperphosphorylated tau (HPtau) 
or transactive DNA binding protein 43 (TDP43) and extracellular accumulation of beta-
amyloid (Aβ) are frequently observed in association with neurodegenerative diseases such 
as Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD).   
 
Almost hundred years ago in 1825, Bouchet and Cazauvielh published an autopsy study in 
which they described increased consistencies in the hippocampus in eight out of eighteen 
patients suffering from epilepsy (EP) (Bouchet, Cazauvieilh 1825). Wilmelm Sommer, in 1880, 
published his own observations of this lesion and described it in fine detail (Sommer W 1880). 
He observed changes in part of the hippocampus, which is now commonly referred to as 
Cornus Ammonis, or Ammon’s horn 1 (CA1) or “Sommer’s sector”, in patients with EP. In 
medicine, the term “sclerosis” is used to describe conditions where there is stiffening of a 
structure, usually caused by a replacement of the normal organ-specific tissue with 
connective tissue, or glia, in the case of CNS. The term originates from the Greek word 
σκληρός meaning “hard”.  Nowadays hippocampal sclerosis (HS) is accepted as the most 
typical finding in refractory temporal lobe epilepsy (TLE), which is the most common form 
of focal epilepsy encountered in adults (Cendes et al. 2014). 
 
Approximately 100 years after these important observations by Sommer, a morphologically 
identified structure resembling a lesion was described in elderly subjects with dementia 
(Volpe, Petito 1985, Dickson et al. 1994, Jellinger 1994). In association with dementia, the HS 
like lesion has been most commonly defined as selective neuronal loss and gliosis in the CA 
1 region and the subiculum.  This is a relatively common autopsy finding, especially in the 
oldest age group. The prevalence of this lesion in autopsy series of demented subjects ranges 
approximately from 2.8% to 13 %, depending on the selection of cases (Jellinger 2000, Barker 
et al. 2002, Leverenz et al. 2002, Beach et al. 2003, Marshall et al. 2005, Attems, Jellinger 2006, 
Nelson et al. 2011b). In rare cases, it may be the only neuropathological finding explaining 
dementia and in such circumstances the term “pure HS” has been used.  
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HS can be seen in association with AD, vascular diseases and FTLD. The TDP43 
proteinopathy was initially described in subjects with FTLD (Neumann et al. 2006, Arai et al. 
2006), but later studies have shown that it can be seen in association with numerous 
neurodegenerative diseases as well as being present in normal ageing (Uchino et al. 2015). 
However, the use of the term HS by neuropathologists has been inconsistent. 
Neuropathology is a discipline which is based on the subjective assessment of visual 
impressions produced after applying various methodologies and this may cause 
discrepancies between different observers, as has been seen in various inter-rater studies 
(Mirra et al. 1994, Alafuzoff et al. 2008a, Alafuzoff et al. 2008d, Alafuzoff et al. 2009a). In order 
to make clinicopathological and genetic studies more comparable and trustworthy, 
neuropathological lesions have to be well characterized and there is a need for consensus-
based reproducible assessment strategies and criteria for identifying different lesions from 
tumors to neurodegeneration. 
 
This study has assessed the prevalence of hippocampal lesions in a large post-mortem cohort 
and described five different types of hippocampal lesions. The association of hippocampal 
alterations with cardiovascular risk factors was examined. The reproducibility of the 
proposed classification stategy was tested in an inter-rater trial with four experienced 
neuropathologists. The incidence of TDP43 pathology was evaluated in our material and 
finally it was determined whether an association could be found between this pathology and 
EP.  The availability of such a large non-selected autopsy cohort from a period on ten years 
with 1388 subjects made it possible to assess these lesions in a unique way. The material 
covers practically the whole human lifespan and is thus different from most other autopsy 
series which have been based primarily on study cohorts of dementia patients.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
2 Review of the literature 
2.1 GENERAL ASPECTS OF HUMAN HIPPOCAMPUS 
On August 25th 1953, American neurosurgeon William Beecher Scoville performed a bilateral 
surgical destruction of the inner aspect of the temporal lobes of his 27 year old patient H.M, 
suffering from drug-refractory EP, in an attempt to control his seizures. The operation indeed 
alleviated his symptoms, but resulted in “striking and totally unexpected grave loss of recent 
memories” (Scoville, Milner 1957). In humans, a lesion restricted to the CA1/subiculum 
region of hippocampus (Rempel-Clower et al. 1996), or bilateral hippocampal volume 
reduction of more than 30 % (Vargha-Khadem et al. 1997) is sufficient to evoke severe 
amnesia with both episodic and spatial memory impairment. These observations highlight 
the pivotal role of the hippocampal formation in complex memory functions. The 
hippocampus is a group of many millions of neurons organized into a very unique network, 
which has fascinated the early anatomists since the times of ancient Egypt. Today it is still 
widely studied from different aspects as there is a broad spectrum of diseases and disorders 
affecting this structure. In addition, the dentate gyrus (DG) part of hippocampus is one of the 
two brain areas in which adult neurogenesis has been widely recognized (Kaplan, Hinds 
1977). 
2.1.1 Neuroanatomy of human hippocampus 
The hippocampus is one of the brain structures constituting the limbic system. In the human 
brain, it is located in the floor of the temporal horn of the lateral ventricle and it consists of 
two C- or V-shaped interlinked structures, the hippocampus proper (Cornu Ammonis, CA) and 
the dentate gyrus (DG). The other regions, which are anatomically and functionally part of the 
hippocampal formation are the subiculum, presubiculum, parasubiculum as well as the 
entorhinal cortex (Amaral, Lavenex 2007). Members of the Alexandrian school of medicine 
studied human anatomy and were impressed by this structure, which they thought 
resembled the coiled horns of a ram (Andersen et al. 2007b). In the sixteenth century, the 
anatomist Anantius (1587) observed similarities in the form of human hippocampus and the 
short-snouted sea horse H.hippocampus. The main, or intraventricular, portion of the human 
hippocampus was first described by the German anatomist Duvernoy in 1729. Others viewed 
the hippocampus as resembling a ram’s horn and De Garengeot (1742) named the 
hippocampus “cornu ammonis” or “Ammon’s horn” after the mythological Egyptian god 
Amun Kneph, whose symbol was a ram (Andersen et al. 2007b).   
 
The Spanish pathologist, histologist and neuroscientist Santiago Ramón y Cajal, Nobel 
laureate in 1906, described anatomically the different neuronal types and intrinsic circuitry 
of the hippocampal formation in rodents and other species (Andersen et al. 2007a). He 
divided the hippocampus into two regions; the region including the DG was named regio 
superior and the region that follows it, regio inferior. Raphael Lorente de Nó, a neuroscientist 
and a student of Ramón y Cajal, further extended the work of his teacher.  In 1934, he 
described many detailed networks of interconnected neurons and divided the hippocampal 
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formation into four divisions, CA1-CA4, terms which are still universally used (Amaral, 
Lavenex 2007).  He defined the CA2 region as a narrow area of cells between the CA3 and 
CA1 regions, which is not innervated by the mossy fibers. However, the existence of the CA2 
region is still somewhat controversial. He defined the CA4 region as a layer of the DG. It is 
now agreed that the term hippocampus should be used for the CA 1-4 regions whereas the 
term hippocampal formation is applied to refer to a group of adjoining regions including the 
DG, hippocampus, subiculum, presubiculum, parasubiculum and entorhinal cortex (Amaral, 
Lavenex 2007). The principal cellular layer in the hippocampus proper is called the 
pyramidal cell layer, which is dense in CA1 and more loosely packed in CA2 and CA3  
(Amaral, Scharfman & Lavenex 2007). The DG has three layers, the molecular layer is 
superficially closest to the hippocampal fissure and the granular cell layer (GCL) is located 
deeper than the molecular layer and made up of a densely packed layer that is normally four 
to eight granule cells thick. The third layer is constituted by the polymorphic cell layer 
(Amaral, Lavenex 2007).  
 
 
 
Figure 1. Hippocampal subfields as seen after H&E staining. The section is from the level of 
the lateral geniculate body. SU – subiculum, DG – dentate gyrus, CA cornu ammonis. 
 
 
The hippocampal formation has unique neuronal connections. It is widely accepted that the 
entorhinal cortex can be considered as the first stage in the intrinsic hippocampal circuit. The 
projections from the entorhinal cortex to the DG form part of the major hippocampal input 
pathway called the perforant path. Neurons in layers II and III of the entorhinal cortex project 
to the DG and the CA3 subfield via the perforant pathway. Neurons in layer III of the 
entorhinal cortex project to the CA1 region and the subiculum via the perforant and alvear 
pathways. The GCL of the DG projects to the CA3 region via the mossy fiber projections. The 
 
 
 
pyramidal neurons in CA3 region project to CA1 via the Schaffer collaterals, which were 
discovered by the Hungarian anatomist Karl Schaffer (Schaffer 1892). Then, the pyramidal 
cells in CA1 project to the subiculum and both CA1 and the subiculum project back to the 
deep layers of the entorhinal cortex (Amaral, Lavenex 2007).  
 
The hippocampus receives its blood supply mostly from the posterior cerebral artery (ACP) 
and its multiple arterial branches, which can be divided into the anterior, middle, and 
posterior groups in relation to the hippocampal head, body and tail. The middle 
hippocampal artery has several branches providing blood to the body of the hippocampus 
and to the subiculum  (Marinkovic, Milisavljevic & Puskas 1992). 
 
2.2 HIPPOCAMPUS AND DISEASE 
2.2.1 Hippocampus and cerebrovascular diseases 
The term “Cerebrovascular diseases” has been broadly used to include many different types 
of diseases. These diseases are especially prevalent in the oldest old population (Garde et al. 
2000, Polvikoski et al. 2010, Nelson et al. 2011a). Cerebrovascular disease in the context of 
dementia and neurodegeneration is still a rather vague subject without any clear uniformly 
accepted neuropathological guidelines and classifications.  
Hippocampus and especially the CA1 region are widely believed to be one of the most 
vulnerable structures in the mammalian brain (Schmidt-Kastner, Freund 1991). Animal 
studies have shown that even transient global forebrain ischemia induces extensive neuronal 
death in the CA1 region as observed in rats (Bendel et al. 2005) and chronic cerebrovascular 
insufficiency induces dementia-like deficits in aged rats (de la Torre et al. 1992). 
Experimentally it has been shown that hippocampal neurons do not die immediately, but 
death occurs within hours or one day after global  (Kirino 1982, Kirino, Tamura & Sano 1984, 
Kirino, Sano 1984) or focal  (Nakano, Kogure & Fujikura 1990) ischemia.  Excitotoxicity, 
especially mediated by glutamate, is believed to be a link between ischemia and neuronal 
death  (Lai, Zhang & Wang 2014). Experimentally it has been demonstrated that a short 
ischemic episode induces a progressive decrease in synaptic numbers in the rat CA1 area, 
exceeding 30% on the first day and 65% at seven days after the occlusion of the blood supply 
(Kovalenko et al. 2006). The human CA1 region, the Sommer’s sector, is similarly vulnerable 
to hypoxic insults ( Petito et al. 1987, Ng et al. 1989). The different subfields in hippocampus 
have been shown to be differentially affected by different pathological mechanisms 
(Hatanpaa et al. 2014) and that hippocampal neuronal atrophy is an important substrate for 
dementia in delayed poststroke dementia (Gemmell et al. 2012). Del Ser and coworkers 
studied the characteristics of AD with and without cerebral infarcts and noted that HS like 
lesions were present in 7 % of (n=57) of AD patients and the two groups differed with respect 
to the presence of hippocampal microinfarcts and white matter lesions (Del Ser et al. 2005).  
In the study of Vinters and coworkers, it was shown that more than 50% of subjects with 
ischemic vascular dementia had suffered a hippocampal injury (Vinters et al. 2000). In the 
study of Dickson, it was demonstrated that arteriolosclerosis and vascular risk factors 
(hyperlipidemia, hypertension, diabetes mellitus, peripheral artery disease and 
cardiovascular disease) were very common in subjects with HS-aging (Dickson et al. 1994). 
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Histologically the earliest finding in an acute anoxic-ischemic injury is the “red neuron 
change” in H&E stained sections which is commonly seen in normal routine 
neuropathological practice. This change appears 12 to 24 hours after the insult. Later changes 
include tissue infiltration by neutrophils, necrosis of tissue, influx of macrophages, vascular 
proliferation and reactive gliosis. After approximately two weeks, the necrotic tissue is 
removed. It has been shown that an anoxic-ischemic injury may result in two types of 
alterations, a classic microinfarct with cavitation, macrophages, and prominent capillaries or 
 
 
 
in cases where there is a more chronic cerebral insufficiency, an injury with neuronal loss 
without cavitation may occur (Leifer, Kowall 1993, Taraszewska et al. 2002). Interestingly, it 
has been reported that the presence of vascular disease increases the accumulation of HPtau 
in the CA1 region in cases of mild AD, but reduces the extent of paired helical filament 
formation (in hippocampal CA2/2 and CA4 regions) in cases with severe AD pathology 
(Smith et al. 2000). Overall, in the elderly it is very common to have comorbid pathologies 
contributing to the clinical phenotype (Rahimi, Kovacs 2014). 
2.2.2 Alzheimer’s disease  
AD is the most common progressive neurodegenerative disease worldwide resulting in 
severe cognitive impairment and eventually leading to death, usually within 10-15 years 
from the onset of symptoms. The typical clinical symptoms of AD are memory impairment, 
executive dysfunction, visuospatial difficulties, aphasia, apraxia and agnosia and behavioral 
problems. Senile plaques (SP) and neurofibrillary tangles (NFT) were first described by the 
German psychiatrist Alois Alzheimer at the beginning of the 20th century. Using the 
Bielchowsky reduced silver method, he described these lesions in the brain of a 51-year old 
patient Auguste Deter presenting with dementia. Since then, the pathology of AD has been 
widely studied and currently it is generally agreed that the neuropathologically characteristic 
hallmark lesions of AD include loss of neurons and synapses, extracellular Aβ aggregations 
as diffuse, focal or stellate deposits and HPtau accumulation in the neuronal cytoplasm as 
paired helical filaments that form NFTs and neuropil threads. There is a build-up of thick 
tortuous HPtau containing neurites in the axons which make up the neuritic corona of 
neuritic plaques  (Duyckaerts, Delatour & Potier 2009).  
The diagnostic hallmark lesions can be considered as “positive signs” i.e. the extracellular 
accumulation of Aβ and intracellular aggregation of HPtau proteins since the negative signs, 
i.e. neuronal and synaptic losses, are difficult to evaluate objectively and are thus currently 
not a part of the neuropathological diagnosis of AD (Duyckaerts 2015a). In 1991, Braak and 
Braak described the progression of neurofibrillary pathology in the cerebral cortex (Braak, 
Braak 1991). Their staging system is based on the stereotypical topographical distribution of 
NFTs and neuropil threads using the paraffin sections and immunochemistry (using the AT8 
antibody) (Braak et al. 2003a). This antibody is commonly used by neuropathologists and is 
considered as reproducible when the lesions are substantial (Alafuzoff et al. 2006, Alafuzoff 
et al. 2008b). The current understanding is that certain nuclei such as locus coeruleus and 
Raphe are initially affected, and this is followed by damage in the trans-entorhinal and 
entorhinal cortices (stages I and II) the hippocampus (stages III and IV) and finally in the 
isocortex (stages V-VI) (Braak et al. 2006). In addition, hippocampal HPtau pathology has 
been shown to relate to the hippocampal neuroanatomical connections (Lace et al. 2009).  In 
subjects with AD, the accumulation of TDP43 is found in 19-57% of the cases. On average, 
these subjects are older at the time of death (Duyckaerts 2015b). An HS like lesion is a 
relatively common finding in subjects with AD (Dickson et al. 1994, Attems, Jellinger 2006, 
Amador-Ortiz et al. 2007a). 
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2.2.3 Frontotemporal lobar degeneration  
 
Frontotemporal lobar degeneration (FTLD) is the most frequent early-onset dementing disease 
after AD. It has a worldwide distribution affecting about 20% of presenile patients with both 
men and women being affected  (Knopman, Roberts 2011). Terminologically FTLD is a broad 
umbrella under which many neurodegenerative diseases affecting preferentially the frontal 
and temporal lobes are typically placed. At present, the group of diseases is quite heterogenous 
in terms of genetics, neuropathology and clinical symptoms. The current understanding is that 
clinically FTLD may present as one of three syndromes: a behavioral-dysexecutive disorder 
(behavioral-variant frontotemporal dementia, bvFTD), language disorders and motor 
disorders including ALS/MND, corticobasal syndrome and progressive supranuclear palsy 
syndrome. It is not uncommon that features of more than one phenotype may be present as 
the disease progresses. HS like lesions are found in approximately 70% of cases of FTLD with 
TDP43 inclusions (Josephs et al. 2009). As in other proteinopathies, the diseases are currently 
believed to be caused by a pathological aggregation of misfolded proteins in either neurons, 
glial cells, or both (Hortobágyi, Cairns 2015).  
The current molecular classification divides FTLD into the following categories and 
subtypes:  
 
 
Figure 2. Neuropathological phenotypes of FTLD (adapted from Kovacs and Cairns (Kovacs, 
Cairns 2015). 
 
Abbreviations: aFTLD-U, atypical frontotemporal lobar degeneration with ubiquitinated 
inclusions; AGD argyrophilic grain disease; ALS amytrophic lateral sclerosis (also referred 
 
 
 
to as “motor neuron disease,” MND; BIBD, basophilic inclusion body disease; CBD, corticob 
asal degeneration; DLDH, dementia lacking distinctive histology; FTLD, frontotemporal 
lobar degeneration;FTD-3, frontotemporal dementia linked to chromosome 3; FUS, fused-in- 
sarcoma gene; GGT, globular glial tauopathy; MAPT, microtubule-associated protein tau 
gene; NFT, neurofibrillary tangle; NIFID, neuronal intermediate filament inclusion disease; 
NOS, not otherwise specified; PiD, Pick’s disease; PSP, progressive supranuclear palsy; TDP, 
transactive-response binding protein; UPS, ubiquitin-proteasome system. (Mackenzie et al. 
2010, Mackenzie et al. 2011). 
2.3 HIPPOCAMPUS AND PROTEIN ALTERATIONS 
2.3.1 Hyperphosphorylated tau  
Tau is a highly soluble, natively unfolded microtubule-associated protein, which is mainly 
concentrated in axons. It binds to microtubules and is believed to stabilize their structure. 
(Weingarten et al. 1975). Six tau isoforms are expressed in the adult human brain via 
alternative mRNA splicing of the MAPT gene located on chromosome 17q21 (Goedert et al. 
1989, Giacobini, Gold 2013, Spillantini, Goedert 2013). Tau hyperphosphorylation is the most 
important modification in neurodegenerative diseases (Grundke-Iqbal et al. 1986, Iqbal et al. 
2009). Accumulation of HPtau in the cell body or in the processes of neurons or glia is referred 
as tauopathy in contemporary neuropathology. The terminology of primary tauopathies 
overlaps with the modern classification of frontotemporal lobar degeneration. Pick’s disease 
(PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic 
grain disease (AGD), neurofibrillary tangle-only dementia (NFT-dementia) and a very 
recently characterized entity of globular glial tauopathies (GGT) are currently understood as 
primary tauopathies (Kovacs 2015). Apart from these, HPtau pathology has been associated 
with AD. In neuropathological practice, numerous antibodies directed against the various 
epitopes of the tau protein have been developed; currently the most commonly used is the 
monoclonal antibody, AT8. In an interlaboratory assessment of 25 independent evaluators, 
the AT8 antibody was shown to be robust and reproducible when the lesions were 
substantial (Alafuzoff et al. 2008b).  
2.3.2 Beta-amyloid  
In 1984 Glenner and Wong, isolated a 4200 dalton polypeptide Aβ, from amyloidotic vessels of 
AD and Down syndrome patients (Glenner, Wong 1984) and soon afterwards Masters and 
coworkers found the same polypeptide in SPs (Masters et al. 1985). In 1989, a study was 
published by Grundke-Iqbal and coworkers in which Aβ was reported in intracellular 
compartments in the human brain (Grundke-Iqbal et al. 1989). Currently it is accepted that the 
Aβ peptide is cleaved from its precursor protein amyloid precursor protein (APP) by two 
sequential enzymatic activities, β-secretase cleaving APP in its extracellular domain leaving a 
fragment called C99 which is subsequently secondarily cleaved by the transmembrane 
gamma-secretase, a complex which includes presenilin (PSEN) (Goedert, Spillantini 2006, 
Selkoe 2008). While Aβ is a normal peptide with still mainly unknown physiological functions, 
amyloid plaques are neuropathological alterations detected in subjects with AD. If the 
production and cleavage of Aβ are not balanced, then Aβ accumulation occurs. Gamma-
secretase cleaves the C terminus of C99 between amino acids C50 and C33, and the most 
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common forms being Aβ-40 and Aβ-42. The types of Aβ deposits encountered in 
neuropathological practice are broadly distinguished as diffuse, stellate and focal (Duyckaerts 
2015a). In the brain of normal young adults, depositions of Aβ are not generally seen but 
deposition of Aβ may occur in intellectually normal aged subjects. Depositions of Aβ in the 
form of plaques are seen in subjects with mild cognitive impairment and in full-blown AD as 
well as in patients with trisomy 21  (Duyckaerts, Delatour & Potier 2009). Autosomal dominant 
mutations in the APP as well as in the genes coding for PSEN1 and PSEN2 are causes of 
familial, often early-onset AD (FAD) (Loy et al. 2014). In 2002, Thal and coworkers described a 
sequential classification for the progression of the parenchymal Aβ in AD in five different 
phases and in phase three, the hippocampus becomes affected (Thal et al. 2002b). In addition 
to the parenchymal deposits of Aβ, cerebral amyloid angiopathy (CAA) is characterized by the 
deposition of Aβ to the leptomeningeal and intracortical cerebral blood vessel. CAA is 
relatively commonly seen in subjects with AD and it increases the risk for lobar intracerebral 
haemorrhages and microbleeds (Thal et al. 2008, Attems et al. 2011). Thal and coworkers have 
identified three topographical stages in CAA: the isocortex being involved in stage 1, the 
allocortex, cerebellum and the midbrain in stage 2 and the basal ganglia, thalamus, pons, and 
medulla oblongata in stage 3 (Thal et al. 2008). According to the vessels involved, there are two 
major types of CAA, angiopathy with capillary involvement as type 1 and without capillary 
involvement as type 2 (Thal et al. 2002a). CAA type 1, i.e. with capillary Aβ deposits, has been 
shown to represent the apoliprotein E (APOE) epsilon4-associated subtype of AD with its 
distinctive neuropathological features (Thal et al. 2010). 
2.3.3 TDP43  
Transactive response DNA-binding protein of 43 kilodaltons (TDP43) is a highly conserved 
414 amino acid 43 kDa nuclear protein, which was first described as a binding protein of a 
polypyrimidine-rich motif of HIV transactive response DNA (Ou et al. 1995). Normally it is 
abundantly expressed in different tissues including heart, lung, liver, spleen, kidney, muscle 
and brain (Buratti et al. 2001). Subsequently in 2006, it was identified as the ubiquitinated 
pathological protein as a major constituent of the proteinaceus inclusions that characterize 
most cases of frontotemporal dementia (FTD) with ubiquitinated inclusions (FTD-U) and the 
majority of sporadic amyotrophic lateral sclerosis (ALS) cases as well as some familial ALS 
cases (Neumann et al. 2006, Arai et al. 2006). TDP43 is normally a protein regulating RNA in 
a variety of ways and as in other proteinopathies, pathological TDP43 aggregates are 
ubiquitinylated and phosphorylated and since the nominal studies, TDP43 protein is now 
agreed to be linked to neurodegeneration, for review see  (Lee, Lee & Trojanowski 2011).  
Since the discovery of TDP43, this protein has been demonstrated to be found in the brain of 
subjects with pathologically diagnosed AD with the prevalence ranging from 19 to 57%. 
(Amador-Ortiz et al. 2007b, Higashi et al. 2007, Hu et al. 2008a, Josephs et al. 2008, Uryu et 
al. 2008a, Arai et al. 2009a, Kadokura et al. 2009, Lippa et al. 2009, Bigio et al. 2010a, King et 
al. 2010, Davidson et al. 2011a, Robinson et al. 2011, Wilson et al. 2013, Josephs et al. 2014a, 
Josephs et al. 2014b, Nag et al. 2015). The subjects with AD and TDP43-pathology present 
with a greater cognitive impairment, have a more rapid cognitive decline, and increased 
hippocampal atrophy (Josephs et al. 2008, Nelson et al. 2008, Wilson et al. 2013). The 
likelihood of having concomitant TDP43 pathology increases with age (Josephs et al. 2014b). 
In the brain of subjects with AD TDP43-pathology is usually seen in the form of neuronal 
 
 
 
cytoplasmic inclusions, dystrophic neurites, or neuronal intranuclear inclusions and these 
are most frequently found in the hippocampus, amygdala, and temporal cortex (Amador-
Ortiz et al. 2007a, Amador-Ortiz et al. 2007b, Hu et al. 2008b, Uryu et al. 2008a, Josephs et al. 
2014a).  
In addition to the neurodegenerative processes discussed above, TDP43-pathology has been 
documented in other neurodegenerative diseases. These include the Guam parkinsonism 
dementia complex (Hasegawa et al. 2007), dementia with Lewy bodies (DLB) (Nakashima-
Yasuda et al. 2007a), familial British dementia (Schwab et al. 2009), corticobasal degeneration 
(Uryu et al. 2008a) and in some series of Pick’s disease (Arai et al. 2006, Freeman et al. 2008), 
dementia with argyrophilic grains (Fujishiro et al. 2009), Perry syndrome (Wider et al. 2009), 
diffuse neurofibrillary tangles with calcification (Habuchi et al. 2011), progressive 
supranuclear palsy (Massey et al. 2009, Yokota et al. 2010)  and dementia pugilistica or 
chronic traumatic encephalopathy (CTE) (King et al. 2010, McKee et al. 2010). In Huntington’s 
disease, a neurodegenerative disease characterized by the presence of the pathological 
protein huntingtin, TDP43 has been reported to co-localize with huntingtin protein in 
dystrophic neurites and different intracellular inclusion but not in intranuclear inclusions 
(Schwab et al. 2008). In the longitudinally tracked population-based study conducted by 
Keage and coworkers, TDP43 pathology was present in 27% of the sample (n=228), in 36% of 
those with clinical dementia and 18% without dementia (Keage et al. 2014). 
Similarly to other proteinopathies, TDP43-pathology in association with AD affects different 
brain regions in a time-dependent manner and different stages have been described by 
Josephs and coworkers (Josephs et al. 2014a). In stage I, the pathology is restricted to 
amygdala, in stage II, the entorhinal cortex and subiculum become affected, in stage III the 
dentate gyrus and occipitotemporal cortices display TDP43-pathology, in stage IV, the 
inferior temporal cortex is affected and finally in stage V, the frontal cortex and basal ganglia 
show signs of damage. The affected neurons display a characteristic loss of normal TDP43 
from the nucleus and solid inclusions in the cytoplasm (Neumann et al. 2006). There is 
evidence for sequential propagation of TDP43-pathology in ALS (Brettschneider et al. 2013) 
and four stages of the disease have been proposed. In stage 4, the anteromedial areas of the 
temporal lobe and the hippocampus have displayed the involvement of TDP43-pathology. 
Two main types of cortical phosphorylated TDP43 intraneuronal inclusions have been 
identified in the behavioral variant FTLD (bvFTD) and these are characterized by either 
perikaryal TDP43-inclusions (cytoplasmic type) or long aggregates in dendrites (neuritic 
type) and four patterns of distribution of TDP43-pathology in bvFTD have been proposed 
with hippocampal involvement in pattern II (Brettschneider et al. 2014).  
In the study of Lee and coworkers, TDP43-pathology was not observed in association with 
different anoxic, ischemic and neoplastic lesions of the central nervous system (Lee et al. 
2008a) but TDP43 pathology has not been reported to be present in the HS related to temporal 
lobe epilepsy (Lee et al. 2008a, Bandopadhyay et al. 2014). Very recently, TDP43 has been 
reported to be expressed in epilepsy-related glioneuronal tumours, raising completely new 
questions (Prabowo et al. 2015). 
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and four stages of the disease have been proposed. In stage 4, the anteromedial areas of the 
temporal lobe and the hippocampus have displayed the involvement of TDP43-pathology. 
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2.3.4 α-Synuclein (α-S) 
 
αS is an abundantly expressed natively unfolded 140 amino acid neuronal protein encoded 
by the SNCA gene on 4q21 and predominantly localized in the presynaptic terminals. The 
exact physiological function of αS is still not known, but it has been claimed to be involved 
in maintaining a supply of synaptic vesicles in the presynaptic terminal.  (Kim, Kagedal & 
Halliday 2014). The SNCA missense mutation Ala53Thr was the first causal mutation 
identified in dominantly inherited Parkinson’s disease (PD) (Polymeropoulos et al. 1997). In 
modern neuropathological practice, the neurodegenerative diseases in which pathological 
accumulation of αS is regarded as the primary alteration are referred to as synucleinopathies. 
The group of primary α-synucleinopathies includes PD, dementia with Lewy bodies (DLB) 
and multiple system atrophy (MSA) and neuroaxonal dystrophies. In addition, αS is often 
found secondarily in other neurodegenerative disease such as AD, in which the aggregates 
are mostly detected in the amygdala (Lippa et al. 1998, Arai et al. 2001).  The 
neuropathological diagnosis of α-synucleinopathies is based on observing αS aggregates in 
the form of intracellular Lewy bodies (LB) or Lewy neurites in neuronal processes (Lewy 
1912, Goedert et al. 2013, McCann et al. 2014, Alafuzoff, Parkkinen 2014). Hippocampal αS 
pathology has been shown to associate with dementia in PD (Hall et al. 2014) and CA2, CA3 
and entorhinal cortex have been shown to be mostly affected by Lewy neurites and Lewy 
grains (Armstrong et al. 2014). In addition to neurodegenerative diseases, αS aggregates are 
a fairly common finding in aged subjects without neurological symptoms (Jellinger 2004, 
Parkkinen et al. 2005). Similarly to HPtau in AD, αS pathology seems to progress in a 
stereotypical manner and thus several schemes for staging have been developed (McKeith et 
al. 1996, Braak et al. 2003b, Alafuzoff et al. 2009a). There are numerous antibodies in use for 
detecting αS. In an interlabotarory study with 22 participants, over 80 % agreement in both 
typing and staging of αS pathology was achieved after applying a protocol designed by the 
BrainNet Europe (BNE) consortium and using a monoclonal primary antibody directed 
against αS (Novocastra/NCL-ASYN, clone KM51, dilution 1:1000) (Alafuzoff et al. 2009b). As 
with the other proteinopathies discussed previously, concomitant pathology is not 
uncommon in synucleinopathies. In the staging scheme of αS PD proposed by Braak and 
coworkers, hippocampal αS pathology is seen in stage 4 (Braak et al. 2003a).  
2.3.5 p62/Sequestosome 1 
 
p62/Sequestosome 1 (p62/SQSTM1) is a highly conserved multifunctional protein involved 
in several cellular processes and it has been linked to age-related pathologies, inclusion body 
myositis, age-related metabolic dysfunction, chronic liver disease and neurodegenerative 
diseases, for review see (Bitto et al. 2014). The accumulated protein aggregates seen in many 
neurodegenerative diseases consisting of αS, HPtau, polyglutamine proteins and TDP43 have 
been shown to display p62/SQSTM1 immunoreactivity  (Kuusisto, Salminen & Alafuzoff 
2001) and thus p62 has been recommended to be used in neuropathological diagnostics; it is 
an especially good stain for screening for inclusions in different neurodegenerative diseases  
(Kuusisto, Kauppinen & Alafuzoff 2008). However, pretangles and grainy αS aggregates are 
not visualized  (Kuusisto, Parkkinen & Alafuzoff 2003a).  
   
 
 
 
2.4 HIPPOCAMPAL SCLEROSIS IN AUTOPSY STUDIES 
Dementia can be defined as a non-specific clinical syndrome that is characterized by a state 
of cognitive impairment and is often associated with memory, language, behavioral and 
motor disturbances. Generally, dementia is a syndrome that may be caused or characterized 
by multiple cognitive deficits, which include memory impairment and at least one of the 
following symptoms: aphasia, apraxia, agnosia or disturbance in executive functioning. 
Social or occupational function is also impaired (American Psychiatric Association 1994). It 
was estimated that in 2010, 35.6 million people were suffering from dementia worldwide and 
this number is expected to double every 20 years, thus approximately 70 million people will 
suffer from dementia in 2030. In a systematic review of the global literature, the age-
standardized prevalence of dementia for those aged ≥ 60 years has varied between 5% and 
7% in most regions of the world (Prince et al. 2013). In the context of patients presenting with 
clinical cognitive impairment, hippocampal alterations have attracted more interest during 
the last thirty years. During this time, dementia has become a major health concern and a 
worldwide economical issue as the world’s population is aging.  
The HS like lesions found in association with dementia attracted some interest in the 1980’s 
and in 1985, Volpe and Petito described two cases of “dementia with bilateral medial 
temporal lobe ischemia”(Volpe, Petito 1985) and considered these lesions to be of hypoxic-
ischemic in origin. In 1986, Clark and coworkers published an article on “primary 
degenerative dementia without Alzheimer pathology” and noted hippocampal and temporal 
lobe sclerosis in 3 out of 22 patients (without AD-pathology) (Clark et al. 1986). In 1989, a 
case report was published by Zweig and his coworkers of a patient with AD and HS like 
lesions (Zweig et al. 1989) and in 1990 Knopman and coworkers showed that “dementia 
lacking distinctive histological features”, later shown to be a subtype of the FTLD group, may 
have had features of an HS like lesion (Knopman et al. 1990).   
The first autopsy study with a larger cohort was published by Dickson and coworkers in 1994 
(Dickson et al. 1994). This was an important post-mortem study; in it HS was defined as “loss 
of neurons in the vulnerable region of the hippocampus, which corresponds to CA1 and the 
subiculum”. This pattern was seen in 13% of the subjects aged 80 or more and in 26 % of 
patients over the age of 80 presenting with dementia.  In that study, concomitant AD- or 
vascular pathology was noted in most of the cases and thus such cases cannot be regarded as 
“pure HS”, which is a much less common finding. In addition, arteriolosclerosis was 
associated with HS in that study. In a rapid response to this study in 1994 Kurt Jellinger 
partially confirmed the finding of Dickson from his own consecutive autopsy series with the 
exception that in his cohort, the subjects did not have increased cardiovascular morbidity 
(Jellinger 1994). In 1997, Corey-Bloom and coworkers published a study which included 
extensive antemortem testing, showing that HS defined as “severe neuronal loss, spongy 
changes, and gliosis in the hippocampus, specifically CA1 sector and the prosubiculum of 
Ammon’s horn, with usual sparing of the CA2/3 regions” could be considered as a 
neuropathological substrate of dementia (Corey-Bloom et al. 1997). However, in this series 
most of the eight patients also had AD-related changes. 
In 2000, Ala and coworkers investigated material from a dementia brain bank (n=1771) and 
found “pure HS” in 0.4 % of the demented subjects. In these cases, HS was the only 
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neuropathological explanation for the patient’s dementia  (Ala, Beh & Frey 2000).  In a series 
of 128 subjects with prospective neuropsychological evaluations as well as neuropathology, 
20 of subjects were referred to as “dementia of unknown etiology, (DUE)” and HS, as 
described by Dickson in 1994, was seen in 55 % of these cases (Crystal et al. 2000). 
In 2002, Barker and coworkers studied the relative frequencies of different 
neurodegenerative diseases in the State of Florida Brain Bank material (n=382). In that study 
HS, defined as “severe and selective neuronal loss and gliosis in CA1 and the subiculun 
disproportionate to any degenerative pathology”, was observed in 13 % of the subjects. In 
that series, the “pure HS” cases tended to be older and “pure HS” was only seen in 1 % of the 
subjects (Barker et al. 2002).  
White and coworkers analyzed cerebrovascular pathology and dementia in autopsied 
subjects from the Honolulu-Asia Aging Study (n=443) from which 12 % had HS defined as 
“marked neuronal loss and gliosis having sharp margins and being limited to specific parts 
of the hippocampus” (White et al. 2002, White 2009). 
In a community-based study by Leverenz and coworkers, 12 % of 134 subjects with dementia 
had the diagnosis of HS defined as “neuronal loss and gliosis in the CA1 and subiculum” 
(Leverenz et al. 2002). Beach and coworkers published a study in 2003 in which widespread 
neuronal or glial HPtau pathology was detected in 12 of 14 cases with HS and dementia and 
in addition, 8 of 14 of these presented with argyrophilic grains. In that study, the authors 
argued that most cases of HS dementia were actually sporadic multisystem tauopathies. The 
term “hippocampal sclerosis dementia with tauopathy” (HSDT) was suggested to be used 
for such cases (Beach et al. 2003). Hatanpaa, Blass and co-workers identified 18 cases (1 %) of 
hippocampal sclerosis dementia from a brain bank material of 1,730 cases (Blass et al. 2004, 
Hatanpaa et al. 2004). 
In a study published only as an abstract by Marshall and coworkers, 528 consecutive 
autopsies were reviewed. In this cohort, 6.4 % had HS defined as “severe gliosis and neuronal 
loss in CA1 and subiculum”, among these were 3 % nondemented subjects (Marshall et al. 
2005). In 2006, Jellinger and Attems showed from their series of 1000 demented elderly 
subjects that 2.8% of the subjects had HS in addition to other pathologies. In this series, the 
subjects were significantly older than the demented subjects without HS and had more 
cardiovascular disease suggesting that hypoxic-ischemic episodes may have been a causative 
factor for HS (Attems, Jellinger 2006). In 2006, Petersen and coworkers published a study on 
subjects with amnesic mild cognitive impairment (MCI), which can be defined as a state in 
which an individual has an objectively measurable impairment in cognitive functions that 
exceeds the borders of benign absent-mindedness, but does not justify a diagnosis of AD or 
any other dementia disorder  (Petersen et al. 1999). In this study, HS was seen in 13 % of 
subjects with MCI and in 4 % of subjects with probable AD. In that study, two of the three 
cases with HS had argyrophilic grains (Petersen et al. 2006). Saito and Murayama published 
a study in 2007 in which HS was observed in 6 % of subjects with MCI (Saito, Murayama 
2007).  Nelson with his coworkers revealed that HS associated to aging was nearly as 
common as severe AD in old age (Nelson et al. 2008, Nelson et al. 2011b) and in 2011 Nelson 
and coworkers studied the features of HS in advanced age and HS was seen in 9.5 % of aged 
subjects (Nelson et al. 2011b). Pao with his coworkers published a study in which 205 
 
 
 
consecutive autopsied patients with dementia were evaluated and 14 % of these had HS, 
defined as “selective neuronal loss and gliosis without cystic cavitation in the subiculum and 
hippocampal CA1 sector” (Pao et al. 2011a). In the study of Dawe and coworkers in 100 
elderly subjects, 13 % had HS defined as “substantial neuronal loss and gliosis including the 
CA1 sector” (Dawe et al. 2011).  
Zarow and coworkers have shown that HS, defined as severe loss of pyramidal neurons and 
accompanying gliosis graded as none, focal or complete, was seen in 23.8 % of cases including 
subjects with subcortical ischemic vascular dementia (IVD), AD, and normal ageing. Among 
these 130 cases, seven represented “pure HS”, 5.4 % (Zarow et al. 2012a).  Corrada and 
coworkers published a study in the oldest old (90+) and from the autopsied 104 cases, 63 were 
demented and 11 of these had HS (17%) (Corrada, Berlau & Kawas 2012).  
In a series of nondemented aged subjects, HS was seen in 3 % of subjects (Jellinger, Attems 
2012). Very recently, Nag and coworkers published a study of 636 autopsied subjects with 
dementia, probable AD and MCI. In their study, HS was defined as “severe neuronal loss 
and gliosis in the hippocampal CA1 and/or subiculum” and HS was identified in 18% of 
subjects over the age of 90 years and in 9.2% below 90 years (Nag et al. 2015).  
 
 
 
 
Figure 3. Unilateral HS as seen at autopsy. Coronal section is taken at the level of the lateral 
geniculate body. The left hippocampus is atrophic as compared to the contralateral side. 
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2.4.1 HS of aging  
HS of aging (HS-aging) is currently considered as a separate neurodegenerative disease with 
high morbidity affecting individuals over the age of 80 years (Dickson et al. 1994, Leverenz 
et al. 2002, Attems, Jellinger 2006, Zarow, Sitzer & Chui 2008, Nelson et al. 2011a,   Pao et al. 
2011, Zarow et al. 2012b,  Nelson et al. 2013a,  Brenowitz et al. 2014, Ighodaro et al. 2015).  In 
autopsy series, 5-30 % of subjects from the advanced old age have been shown to exhibit HS-
aging pathology (Leverenz et al. 2002, Nelson et al. 2011b, Corrada, Berlau & Kawas 2012, 
Zarow et al. 2012a). The term “HpScl”  (Pao et al. 2011) or “hippocampal sclerosis dementia”  
(Probst, Taylor & Tolnay 2007) can be used interchangeably.  It is noteworthy that clinically, 
HS-aging pathology is often mistakingly attributed to AD (Zarow, Sitzer & Chui 2008, Pao et 
al. 2011, Nelson et al. 2013, Brenowitz et al. 2014).  
The diagnosis of HS-aging is based on the neuropathological findings using consensus based 
criteria (Nelson et al. 2011b, Montine et al. 2012). These include neuronal loss, gliosis and 
atrophy of the hippocampal formation that is out of proportion to the AD-type pathology. 
The key diagnostic feature of HS-aging pathology in H&E stained sections has been 
described as “neuronal dropout in CA1 of hippocampus, subiculum, entorhinal cortex, and 
amygdala. Atrophy can be marked in these areas. In severely affected cases, normal cellular 
components are replaced by reactive astrocytes and the neuropil becomes highly rarefied 
(cell-, and neurite-sparse) or frankly cavitary. Lymphocytic infiltrates or perivascular cuffing 
are not typically seen” (Nelson et al. 2013b). Additional immunohistochemical stains are thus 
required to rule out AD-pathology.  
Hippocampal TDP43-pathology is a common finding in subjects with HS-aging (Amador-
Ortiz et al. 2007a, Amador-Ortiz et al. 2007b, Amador-Ortiz, Dickson 2008, Nelson et al. 
2011a, Nelson et al. 2013a, Nag et al. 2015) occurring in as many of 93% of cases (Zarow et al. 
2012a).  It has been postulated that TDP43-pathology is actually the key difference between 
HS-aging (Nelson et al. 2011c) and HS caused by other mechanisms such as TLE or vascular 
insufficiency (Lee et al. 2008b, Bandopadhyay et al. 2014). Clinically HS-aging has been 
shown to mimic AD (Pao et al. 2011a, Brenowitz et al. 2014).   
 
A recent study by Aoki and coworkers (Aoki et al. 2015) introduced the term “pre-HS” in 
which the hippocampus displayed none to minimal neuronal loss or extracellular 
neurofibrillary tangles with florid TDP43-pathology and in another recent study HS-aging 
was considered as segmental (Ighodaro et al. 2015). 
 
 
 
 
2.5 NEUROPATHOLOGICAL INTER-RATER STUDIES IN 
NEURODEGENERATIVE LESIONS 
Neuropathology and pathology in general is a highly subjective and visual discipline and 
thus there is always a degree of inter-individual variability. This can lead to a discrepancy 
between different observers, which may affect the results in studies. The Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) was funded by the National Institute 
on Aging in 1986 to develop standardized and validated measures for the assessment of AD. 
In 1991, the neuropathology task force of the CERAD introduced the standardized 
neuropathology protocol for refining the diagnostic criteria for assessing AD (Mirra et al. 
1991). However, concerns were raised about intercenter variation in methods and 
interpretation of the CERAD protocol. Subsequently, Mirra and coworkers published an 
interlaboratory comparison study of the neuropathological assessment of AD following the 
CERAD protocol. In that study, 24 neuropathologists from 18 centers determined the rank 
order of severity of AD pathology and semiquantitatively and quantitatively described the 
senile plaque and neurofibrillary tangle frequencies. The inter-rater reliability in ranking the 
ten cases in that study was 75%. Semiquantitative analyses showed reasonable agreement, 
but the quantitative assessment for the plaque and tangle counts did reveal significant 
differences between observers and centers (Mirra et al. 1994).  
Alafuzoff and coworkers from the BNE consortium published a study in 2006 in which the 
reproducibility of the assessments of neuritic plaques and neurofibrillary tangles was 
evaluated (Alafuzoff et al. 2006). In that study, the staining quality and the assessments 
differed between the participants. The study revealed diversity in the staining quality as well 
as in the assesments of neuritic plaques and tangles, with the most problems encountered 
with the Bielschowsky stain followed by the Gallyas stain. It was shown that the most 
uniform staining quality was obtained using the immunohistochemical method for detecting 
hyperphosphorylated tau. In addition, the neuropathological diagnostic protocol which was 
used significantly influenced the agreement and was highest with NIA-Reagan protocol. This 
was further improved by visualization of neurofibrillary tangles using the IHC/HPtau 
method.  
The inter- and intra-rater reliability on staging of sporadic Parkinson disease-related αS 
pathology was evaluated by Müller and coworkers. In that study, six observers from five 
institutions rated 21 cases on the basis of written instructions. The agreement rate was highly 
significant and both inter- and intra-rater reliability were reported to be almost perfect 
(Muller et al. 2005). However, in a larger study conducted by Alafuzoff and coworkers from 
the BNE consortium, the assessment of αS pathology was studied in 17 centers of the 
consortium (Alafuzoff et al. 2008c). In that study, twenty-eight evaluators assessed neuronal 
perikaryal inclusions, neurites, and glial cytoplasmic inclusions. In the first phase of the 
study, the TMA slides were stained with the antibody of the center’s own choice. Fifty-nine 
percent of the sections were good or acceptable in quality and four of nine antibodies used 
performed consistently. However, differences in interpretation and categorization of αS 
structures led to variations in the results reported by the centers. Based on the results of the 
first phase of the study, selected antibodies using designated antigen retrieval methods were 
then applied to TMA slides in the second part of the study. In addition, prior to the second 
phase, the participants underwent a training session conducted by experts on the evaluation 
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of αS IR structures. After the designated methods of both staining and evaluation were 
applied, all 26 subsequently stained sections were evaluated as good or acceptable in terms 
of quality and a high level of concordance in the assessment of the presence or absence of 
specific αS IR structures was achieved. Furthermore, a semiquantitative assessment of αS IR 
neuronal perikaryal inclusions showed agreements ranging from 49% to 82% and the best 
concordance was achieved in cortical core samples. Therefore the authors suggested that 
rigorous methodology and dichotomized assessment should be applied and that a 
semiquantitative assessment could only be justified for the cortical samples.  
Based on the findings from these BNE studies, the inter-laboratory assessments of Aβ-protein 
were studied and published in 2008 (Alafuzoff et al. 2008d). This study with 26 participants 
from 15 centers consisted of two phases. In the initial phase, the TMA sections were stained 
with the antibody of each center’s own choice. Seven antibodies and various pretreatments 
were used. Ninety-two percent of the stainings were good or acceptable in terms of quality. 
The estimation of the presence of Aβ aggregates yielded good results. The quantitative and 
qualitative results showed a poor agreement rate. After the first phase, a joint meeting took 
place and the clone 4G8 was determined to label best the fleecy/diffuse plaques and this clone 
with the formic acid pretreatment was utilized in the second part of the study. All stained 
sections were then good or acceptable in quality and a high level of concordance of the 
dichotomized assessment of plaques and CAA was achieved. It was demonstrated that when 
only one antibody was used, the type of Aβ aggregates (diffuse/cored), type of vessel and 
Vonsattel grade, were not reliably assigned. In addition, the quantification of Aβ lesions was 
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published (Alafuzoff et al. 2009b). In that study, 22 members of the consortium assessed 31 
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coworkers in 2005 (McKeith et al. 2005). When the protocol described by Braak and 
coworkers was used, the agreement rate was only 65% and even as low as 36% in some cases. 
It was demonstrated that an agreement rate of over 80% in both typing and staging of αS 
pathology could be achieved when applying the new protocol, which was jointly designed 
by the consortium. In the most recent BNE study, the assessment of pathology in FTLD with 
TDP43-positive inclusions was analyzed (Alafuzoff et al. 2015). In that study, the agreement 
rates were influenced by the IHC method and by the classification strategy being applied. 
P62-IHC staining showed good and uniform quality of stains, but the most reliable results 
were obtained when specific antibodies directed against TDP43 were utilized. Similarly to 
the previous BNE studies, the assessment of the extent of the lesions consistently achieved 
poor results and thus the consortium suggested that the extent of pathology should not be 
used in the diagnostic consensus criteria.  
2.6 HIPPOCAMPUS, DIABETES AND HYPOGLYCEMIA  
Hippocampus and especially the DG is vulnerable to hypoglycemia and necrosis of the DG 
is sometimes seen under this condition (Kalimo, Olsson 1980, Auer et al. 1984, Auer 2004, 
Languren et al. 2013). This may be caused by a massive amount of the excitatory amino acids 
aspartate and glutamate being released into the extracellular fluid (Auer et al. 1989, Languren 
et al. 2013). In imaging studies using MRI, type 2 diabetes has also been associated with 
hippocampal damage (Gold et al. 2007) and atrophy of the medial temporal lobe structures 
(den Heijer et al. 2003). In the Honolulu-Asia Aging Study, it was shown that elderly people 
with diabetes mellitus had smaller hippocampi than those without diabetes mellitus (Korf et 
al. 2006).  
2.7 HIPPOCAMPUS AND TRAUMATIC BRAIN INJURY  
In addition to the insults discussed above, hippocampal pathology, particularly affecting the 
CA1 region, has also been demonstrated to occur due to acceleration-induced experimental 
head injury in nonhuman primates (Kotapka et al. 1991), fatal non-missile head injury in 
humans (Kotapka et al. 1992), fatal pediatric head injury (Kotapka et al. 1993) and fatal 
human head injury without high intracranial pressure (Kotapka et al. 1994). In a series of 
cases which had resulted in the patient being in a vegetative state after a blunt head trauma, 
hippocampal damage in various sectors was observed in 28 of 35 cases (Graham et al. 2005) 
and in situ fragmentation of DNA in hippocampus has been shown to occur after 12 months 
(Williams et al. 2001). Previously named “dementia pugilistica” after Millspaugh, 
(Millspaugh 1937), chronic traumatic encephalopathy (CTE), which is a progressive 
tauopathy that occurs as a consequence of repetitive mild traumatic brain injury (mTBI), in 
which deposits of HPtau in the form of neurofibrillary tangles have been shown to gather in 
the brain (Omalu et al. 2005, Omalu et al. 2006, McKee et al. 2009, Gavett et al. 2010). Clinically 
the symptoms of this syndrome include irritability, impulsivity, aggression, depression, 
short term memory loss and an increased risk for suicidal behavior (McKee et al. 2009). 
Subsequently, more severe neurological changes occur including dementia, gait and speech 
abnormalities and Parkinsonism and the clinical symptoms may mimic those of other 
neurodegenerative diseases. TDP43-pathology in the form of intraneuronal and intraglial 
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inclusions is a common finding in CTE and deposits of Aβ are relatively rare (King et al. 2010, 
McKee et al. 2010, McKee et al. 2013). The distribution and extent of pathology can be 
classified as stage I-IV and in stage III, the hippocampus is affected (McKee et al. 2013, McKee 
et al. 2014). From imaging studies, it has been suggested that the fornix and hippocampus 
may undergo atrophy after traumatic brain injury (Tate, Bigler 2000).  
2.8 HIPPOCAMPUS, ALCOHOL AND DRUG ABUSE  
Chronic heavy alcohol abuse is associated with structural and functional injury to the brain, 
leading to cognitive impairment and adverse effects on brain function (de la Monte, Kril 
2014). The acute effects of alcohol on the central nervous system are mainly caused by alcohol 
intoxication or hepatic dysfunction leading to encephalopathy and myelopathy. In post-
mortem studies, 75% of chronic alcoholics display signs of significant brain damage or 
degeneration (de la Monte, Kril 2014). Disruption of the limbic circuitry in alcoholics has been 
associated with reduced blood flow to the callosomarginal region, pericallosal region, 
thalamus, hippocampus, parahippocampal gyrus, amygdala, and anterior and middle 
cingular regions (Suzuki et al. 2010). In the study of Kril and coworkers, there was a trend 
towards hippocampal atrophy found in chronic alcoholics, although the difference was not 
statistically significant (Kril et al. 1997). Overall, in the human material, the evidence of 
hippocampal injury caused by alcohol is very limited (Harper 2009) and the cortical atrophy 
may be mostly associated with a loss of synapses (de la Monte, Kril 2014). Relatively little is 
known about the neuropathology of drug abuse, but elevated levels of hyperphosphorylated 
tau and amyloid precursor protein deposition have been detected in the brains, and 
hippocampus, of young drug abusers (Ramage et al. 2005). Neuronal loss in the hippocampal 
formation is frequently seen in chronic drug abusers and this is most likely attributable to 
the toxic effects associated with primary respiratory failure (Oehmichen et al. 1996). Cannabis 
is a widely produced and consumed illicit substance and its abuse has been shown to be 
associated with changes in the hippocampus (Yucel et al. 2008). Methamphetatine users have 
been shown to exhibit smaller hippocampal volumes compared to controls (Thompson et al. 
2004). In addition, “ecstasy”, i.e. 3,4-methylenedioxy-methamphetamine (MDMA) abuse has 
been reported to be associated with reduced glucose metabolic uptake in the amygdala, 
hippocampus, and Brodmann area II (Obrocki et al. 1999).  
2.9 HS AND EPILEPSY 
Neuropathological changes in the human hippocampus in epileptic subjects were first 
described in the first half of the 19th century when Bouchet and Cazauvieilh in a seminal post-
mortem study described lesions of increased consistency involving the hippocampus in 8 of 
18 subjects suffering from EP or “insanity” (Bouchet, Cazauvieilh 1825). However, they did 
not place much emphasis on this finding and it was largely forgotten for some decades. In 
1880, Wilhelm Sommer, a neuropsychiatrist and pathologist, published a remarkable study 
in which he recognized the importance of this lesion. He reviewed the findings from previous 
reports and with his own studies from a total of 90 post-mortem examinations, he carefully 
described the abnormalities within the Ammon’s horn in patients with EP in minute detail 
(Sommer W 1880). He emphasized the importance of the extensive neuronal loss in the 
 
 
 
hippocampal pyramidal cell layer “All pyramidal cells….which are doubtlessly of greatest 
importance for the function of Ammon’s horn are missing”. The anatomical term “Sommer’s 
sector” is still in use today, corresponding to the CA1 region defined later.  Bratz published 
a study in 1889 in which he confirmed the previous findings and described the microscopical 
findings in fine detail. He also observed the sharp interface of neuronal loss between CA1 
and the preserved subiculum and noted the resistance of cell loss in the area now known as 
CA2 (Bratz 1889). It is noteworthy that at this time post-mortem studies conducted on 
subjects with dementia did not receive much attention and were generally regarded as 
unimportant. In the early pioneering studies, it was noted that the pattern of neuronal loss 
displayed some variation. In 1927, Spielmeyer noticed a pattern in some severe cases in which 
all sectors of the hippocampal pyramidal cell layer were affected (Spielmeyer W 1929). Later 
a pattern of neuronal loss restricted to the hilus while sparing CA1 was described by 
Margerison and Corsellis (Margerison, Corsellis 1966). In 1935, Stauder published a study in 
which he correlated Ammon’s horn sclerosis with the symptoms of temporal lobe epilepsy 
in 33 of 36 cases examined post-mortem (Stauder 1935).  
Since the historical studies discussed above, TLE has been regarded as the most common 
form of focal EP in adults  (Hauser, Annegers & Rocca 1996,  Cendes et al. 2014) and HS has 
been accepted as one of the most frequent pathologies underlying drug-resistant EP (Thom 
2014, Cendes et al. 2014). It is a common finding in the syndrome of mesial TLE (MTLE) and 
in a large epilepsy surgical series, its incidence has varied from 34% (Blumcke et al. 2012) to 
66% (de Tisi et al. 2011). In post-mortem studies on epileptic patients, HS has been identified 
in between 31% and 45% of all EP syndromes and in 56% of subjects with the MTLE  
(Meencke, Veith & Lund 1996, Novy et al. 2013). Granule cell dispersion (GCD), was first 
described by Carolyn Houser (Houser 1990); this is characterized by a broadening of the GCL 
above 10 layers (Wieser, ILAE Commission on Neurosurgery of Epilepsy 2004), a vague 
boundary with the molecular layer, and ectopic granule cells separated from the main layer 
by intervening neuropil and it has been found to be present in approximately 50 % of all TLE 
cases (Houser 1990, Blumcke et al. 2009). GCD has been reported to be less common in HS 
associated with neurodegeneration (Bandopadhyay et al. 2014).  
2.10 EPILEPSY, SEIZURES AND ALZHEIMER’S DISEASE  
In the elderly population, seizures and EP are often triggered by traumatic events such stroke 
and head injury or by the progression of neurodegenerative disorders (Cloyd et al. 2006). AD 
and other neurodegenerative diseases represent the presumed etiology for 10% of new onset 
EP in patients older than 65 years  (Hauser, Annegers & Kurland 1993). Patients with 
sporadic AD have been reported to experience a 6- to 10-fold increase in the risk of 
developing clinical seizures (Sjogren, Sjogren & Lindgren 1952, Hauser et al. 1986, Hesdorffer 
et al. 1996). Prospective and retrospective studies have reported great variabilities, ranging 
from 2% to 64%, in the lifetime prevalence of seizures in patients with AD (Sulkava 1982, 
Hauser et al. 1986, Romanelli et al. 1990, McAreavey, Ballinger & Fenton 1992, Mendez et al. 
1994, Volicer, Smith & Volicer 1995,  Hesdorffer et al. 1996, Amatniek et al. 2006, Lozsadi, 
Larner 2006, Rao et al. 2009, Scarmeas et al. 2009, Bernardi et al. 2010). Two large prospective 
cohort studies have estimated that the overall incidence of seizures in subjects with AD to be 
approximately 1 per 200 person-years of observation, which is indicative of a lower 
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frequency than reported in previous studies (Scarmeas et al. 2009, Irizarry et al. 2012). In a 
population-based nested case-control analysis, the incidence rate of EP was claimed to be 
approximately sevenfold in subjects with AD (Imfeld et al. 2013) with the association being 
apparently particularly strong in subjects with dementia onset at a young age (Scarmeas et 
al. 2009). Epilepsy is very frequent in subjects with familial AD resulting from different 
mutations in the APP, the gamma-secretase modulatory genes, PSEN1 and PSEN2. In 
addition to these familial cases, a de novo mutation in PSEN1 may also produce a phenotype 
in which dementia is accompanied by EP (Alberici et al. 2007). With respect to 
neurodegenerative diseases other than AD, there is a lack of studies regarding the incidence 
of seizures and EP. Down syndrome has many neuropathological features of AD and as 
many as 84 % of subjects with both Down syndrome and dementia suffer from seizures 
(Menendez 2005). In animal models of AD, including transgenic animals expressing human 
APP and thus having elevated levels of Aβ, the incidence of seizures was increased during 
the early stages of the disease (Palop, Mucke 2009). 
It has been suggested that the appearance of seizures in patients with AD is a marker for 
cortical neurodegeneration and for late stages of the disease process (Romanelli et al. 1990). 
In the early stages of AD, seizures may reflect an aggressive progression of the disease or 
may be attributable to other factors such as susceptibility to hypersynchronous electrical 
activity (Amatniek et al. 2006, Irizarry et al. 2012). Epileptic activity may also accelerate the 
course of AD. It has been hypothesized that both AD and EP can be viewed as diseases that 
intersect in the hippocampal formation (Noebels 2011).  
 
 
 
 
 
 
 
 
 
3 Aims of the study  
This research project is aimed to characterize the lesions seen in human hippocampus 
associated to various diseases and disorders and to provide diagnostic guidelines when 
assessing these lesions and especially to clarify the use of the term “hippocampal sclerosis” 
in neuropathology. Furthermore, the age-related prevalence of these lesions was studied in 
a large autopsy cohort of adult to aged subjects. The following five questions were considered 
particularly interesting and clinically important. 
 
1. What is the prevalence of hippocampal lesions in non-selected autopsy material?  
 
2. Is an increased cerebro-cardiovascular pathological burden associated with the 
prevalence of ischemic hippocampal lesions?  
 
3. What is the role of TDP43-pathology in hippocampal lesions?  
 
4. Is is possible to obtain a good inter-rater agreement rate when experienced  
neuropathologists assess hippocampal alterations using standardized guidelines? When 
should experienced neuropathologists use the term “hippocampal sclerosis” in post-
mortem diagnostics? Is it possible to clarify the terminology for hippocampal lesions and 
HS?  
 
5. Is there an association between epilepsy in elderly subjects and hippocampal sclerosis? 
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4 Subjects and Methods  
4.1 ETHICAL ASPECTS  
Autopsies including a neuropathological examination were carried out in Kuopio University 
Hospital. The relatives of the deceased had given approval that the autopsy could be 
performed. A standardized neuropathological investigation was carried out in order to 
provide a diagnosis. In this procedure, brain tissue samples were collected in a standardized 
manner as recommended by BNE and embedded in paraffin. Sections were produced from 
these paraffin blocks for diagnostic purposes and stained as recommended by BNE. In all 
studies I to IV, the produced stained sections were reassessed. When needed, additional 
stains were carried out. After reassessment, all sections were returned to the archive. The 
study was authorized by the Research Ethics Committee of the Northern Savo Hospital 
District and the Finnish National Authority for Medicolegal Affairs (3485/(32/200/98). 
4.2 CASE SELECTION  
The study cohort included those subjects who underwent an autopsy including a 
neuropathological examination between the years 1995-2005 in the Department of Pathology 
of the Kuopio University Hospital, a tertiary medical center serving approximately 250 000 
people in eastern and central Finland. The mortality rate of the population in this area is 
approximately 10 per 1000and the autopsy rate during this period was estimated to be 32 per 
100). In study I, 185 subjects that underwent a neuropathological evaluation in 2003 and did 
not display evidence of hippocampal infarcts were included as a control group. In study I, 
subjects with neoplastic process or infectious diseases within the brain as well as cases with 
ruptured aneurysms on cerebral arteries where excluded (n= 34). In studies II and IV, an 
infant aged 7 months was excluded as the focus of these studies was on elderly subjects. 
Subjects who underwent a forensic autopsy were derived from a 6 months period in 1999. In 
Finland, a medical autopsy is performed when it is deemed necessary for determining the 
cause of death or if the relatives are willing that it should be done. According to the Finnish 
legislation, a forensic autopsy should be carried out on all subjects dying at home when there 
is insufficient medical history to assess the cause of death, on all subjects who have died in 
accidents, as victims of homicide of suicide or who were suspected to be victims of 
malpractice. The flowchart (Figure 4) describes the logistics of the present study and the 
demographics of the subjects are described in table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1  
 
Publication 
 
Number of cases  
 
Gender (m/f) 
 
Mean age 
 
I 
 
116 
 
53/63  
 
79±1  
I controls 96 53/43 75±1 
                                
II 
 
250 
 
104/146 
 
78±1 
 
III 
 
251 
 
104/147 
 
77±1 
III controls 9 3/6 77±3 
 
IV 
 
30 
 
11/19 
 
80±2 
4.3 NEUROPATHOLOGICAL EVALUATION  
During 1995-2005, out of 1,900 post-mortem neuropathological evaluations carried out, in 
1,388 (73%) there was available a good representative section of the posterior hippocampus 
taken at the level of the lateral geniculate body. All individuals underwent a systematic 
evaluation of the central nervous system by one experienced neuropathologist. The 
assessment included samples from at least 16 regions: frontal, temporal, parietal, precentral, 
occipital cortices, cingulate gyrus, striatum, basal forebrain including amygdala, thalamus, 
anterior and posterior hippocampus, midbrain including substantia nigra, pons including 
locus coeruleus, medulla, cerebellar vermis and cortex. Additional samples were taken from 
any macroscopically notable lesions. The posterior hippocampal sample (Figure 1) was taken 
at the level where the lateral geniculate nucleus was visible. At this coronal level, the entire 
posterior hippocampus, including all four CA regions (CA1-4) and the dentate GCL are 
clearly and readily identifiable. Grossly apparent hemispheric brain infarcts were noted 
according to their localization by the primary supplying cerebral artery: anterior cerebral 
artery (ACA), medial cerebral artery (ACM), ACP, or cerebellar arteries. It was noted 
whether the gross lesions were located in the “watershed” areas, i.e. the border zones 
between the territories supplied by two major arteries. More samples were taken from 
additional regions depending on the case if it was deemed necessary by the neuropathologist. 
After the standardized dissection protocol, all brains were routinely weighed, evaluated for 
grossly detectable lesions, fixed in 4 % buffered formaldehyde for at least one week and then 
cut into coronal slices of 1 cm in thickness using a long-bladed knife.  
 
The severity of atherosclerosis in the circle of Willis was graded on a four step scale: “none” 
– no atherosclerotic plaques were seen, “mild” – scattered atherosclerotic plaques were seen 
particularly in the areas of bifurcations, “moderate” – atherosclerotic changes were obvious 
as well as focal lesions such that the arterial lumen was obliterated by up to 50 % and “severe” 
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– most of the vasculature was affected and focal lesions were sufficient to cause lumen 
obliteration of at least 75 %.  The standard neocortical samples were routinely taken from the 
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(H&E), which is an old and inexpensive histological stain routinely used in most laboratories.  
4.3.1 Microscopic evaluation 
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Shortly, the “type +” was used when there were histological signs of recent diffuse 
hypoxic/ischemic degeneration of CA neurons. “Type 1” included cases with small (single or 
multiple) infarcts in the CA areas. “Type 2” was used for the cases of extensive, often cavitary 
infarction in CA1. “Type 3” was used for cases with patchy diffuse neuronal degeneration in 
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4.3.2 Immunohistochemistry 
Aβ, HPτ, αS, p62 and TDP43 were manually visualized using immunohistochemical (IHC) 
techniques. The sections were deparaffinized and rehydrated according to the standard 
procedure. Following the pretreatment, the sections were incubated with non-immune 
serum for 30 minutes at room temperature to eliminate nonspecific reactions. The antibody 
(table 2) was applied after the epitope unmasking procedures.  The sections were incubated 
overnight at 4° C. On the following day, the sections were incubated with biotinylated second 
antibody for 30 minutes followed by streptavidin enzyme conjugate (Histostain-Plus kit, 
Zymed, San Francisco, CA, USA) for 30 minutes at room temperature. The presence of the 
strepavidin biotin complex was visualized using VectorRed (Vector Laboratories, 
Burlingame CA), Romulin 3-amino-9-ethyl carbazole chromogen (Biocare Medical, Walnut 
Creek, CA, USA), or diaminobenzidine. All immunostained sections were counterstained 
with Harris’ haematoxylin (Merck, Darmstadt, Germany), dehydrated, and mounted in 
DePex (BDH Laboratory Supplies, Poole, UK). 
Table 2 Immunohistochemistry 
 
Antigen Clone Company Pretreatment Chromogen Dilution 
TDP-43 2E2-D3 Abnova, 
Heidelberg, 
Germany 
autoclave in  
120°C water; 
80% formic 
acid 5 min. 
Romulin AEC 1:1000 
HPTau AT8 Innogenetics, 
Ghent, 
Belgium, BR-03 
None Diaminobenzidine 1:500 
α-Synuclein KM51 NCL-ASYN 
Novocastra, 
Newcastle, UK 
autoclave in 
0.01 mol/L 
citrate buffer  
pH 6.0 and 80% 
formic acid 5 
min. 
Romulin AEC 1:1000 
p62 lck ligand 3 BD Biosciences 
Pharmingen, 
Franklin Lakes, 
NJ, USA 
autoclave at 
120°C in 0.01 
mol/l citrate 
buffer pH6.0 
Romulin AEC 1:1000 
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Figure 4. Flowchart describing the logistics of the study 
 
 
 
 
 
A representative section of the posterior hippocampus was available in 1388 out of 1900 consecutive 
autopsies performed between 1995 and 2005. 
A pathological alteration visualized in H&E stain was seen in 251 (18%) of the cases. Nine control cases 
were included. The H&E stained sections were screened by one or two observers and five different types 
of lesions were identified. 
Inter-rater study with four invited experts assessing the 260 H&E stained sections. IHC stainings were 
performed (HPtau, αS, p62, TDP43) 
Evaluation of medical and 
autopsy records of the 
cases (n=150) with an 
ischemic lesion. A control 
group of 185 subjects 
without a hippocampal 
ischemic lesion was 
included. 
Study I 
Evaluation of TDP43 
pathology and 
neuropathological 
diagnosis of the cases 
(n=250) 
Study II 
Joint meeting with all 
cases (+ IHC stains) 
assessed (n=260). The 
definitions of five 
different types of 
hippocampal lesions 
were agreed on. 
Study III 
Evaluation of the 
medical and autopsy 
records of the 
subjects with a type 
4 lesion (n=30) 
Study IV 
 
 
 
4.4 INTER-RATER ASSESSMENT  
The H&E-stained sections of all included 260 hippocampi were circulated among the four 
participating experts, experienced neuropathologists, without any clinical data except the 
age of the subjects. The four observers were asked to categorize the type of alterations 
observed by light microscopy without the use of any morphometric techniques following the 
instructions provided by the coordinating group. In addition, the participating experts were 
asked to state whether, in their opinion, the lesions represented HS. The participants had the 
opportunity to write their own observations and remarks on the assessment sheets. After 
circulating the sections, the assessment sheets were collected by the coordinating group for 
analysis.  
4.5 JOINT ASSESSMENT AND THE CONSENSUS RECOMMENDATIONS 
After the independent assessments of the H&E-stained sections by the four participating 
experts, the whole study group met to jointly discuss all cases using a multihead microscope. 
This allowed the participants to share the same view of the samples simultaneously. At this 
point, both H&E-stained sections and immunohistochemically stained sections were 
available. The cases were reassessed jointly, and the results of the inter-rater assessment were 
discussed. Those cases with a low agreement rate were discussed in detail, and the pitfalls in 
the assessment leading to different interpretations were identified and agreed on. Based on 
these observations and discussions, the group agreed on definitions to be used when 
assessing hippocampal pathology and for the use of the term “HS”.  
4.6 EVALUATION OF CARDIOVASCULAR PATHOLOGY 
In study I, the cardiovascular pathology was evaluated by grossly assessing the severity of 
atherosclerosis in the large arteries. After opening the thoracic cavity, the hearts were 
weighed and the severity of atherosclerosis in the coronary arteries was evaluated using 
specially designed scissors. The cardiovascular pathology was assessed using a 
cardiovascular index (CVI) as described earlier by Alafuzoff and coworkers (Irina et al. 1999). 
Shortly, the variables taken into account were heart weight (<250, 251-325, 326-400, >400 
grams), severity of coronary arteriosclerosis on a four step-scale, the presence of coronary 
thrombosis, gross lesions consistent with acute myocardial infaction, gross lesions consistent 
with an old myocardial infarction, the severity of generalized arteriosclerosis on a four step-
scale assessed in the aorta, renal arteries, superior mesenteric artery, the severity of 
arteriosclerosis in the circle of Willis on a four step-scale. This gives a numerical sum of 0-15 
for the index.  
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4.7 RAPIDITY OF DEATH 
The rapidity of death was assessed with a four stage categorization: 1) almost instantaneous 
death, i.e. gunshot wound to the heart, drowning, vehicle accident with death at the scene 2) 
death within 24 h of no pre-existing cause and with minimal evidence of cerebral hypoxia, 
i.e. vehicle accident with death from internal bleeding occurring several hours later, sedative 
overdose 3) death within 24 h of existing cause, but with presumption of some cerebral 
hypoxia, i.e. carbon monoxide poisoning 4) slow death occurring over period of > 24 h, i.e. 
death from carcinoma 5 ) slow death with assisted ventilation (Johnston et al. 1997).  
4.8 CLINICAL EVALUATION  
The clinical data for the necessary clinical variables and medical history were collected 
retrospectively from the autopsy referrals and medical records. Additionally, in study IV, a 
clinical neurologist evaluated the medical records from a clinical, especially a neurological, 
viewpoint. The diagnosis of cognitive impairment or dementia was based on the National 
Institute of Neurological and Communicative Disorders and the Alzheimer’s Diseases and 
Related Disorders Association (NINCDS-ADRDA)  (McKhann et al. 1984) and the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-III-R) criteria (American Psychiatric 
Association 1987). However, some of the cases which were classified as without cognitive 
impairment, might have displayed very mild cognitive impairment that had not been 
recognized during the patient’s lifetime, though it is unlikely that the presence of moderate 
or full-blown dementia would have been overlooked. In addition, it was recorded whether 
the medical records showed any indications that the subject had suffered from EP or seizures. 
In study I, the clinical parameters monitored were the presence/absence of common 
cardiovascular and metabolic alterations, i.e., arterial hypertension, peripheral artery disease 
of the lower extremities, coronary disease, myocardial infarct, atrial fibrillation, heart failure, 
transient ischemic attacks (TIA), stroke, diabetes mellitus (both types I and II).  
4.9 STATISTICAL ANALYSES  
IBM SPSS (IBM, Armonk, NY, USA) versions 20, 21 and 22 for Windows and Macintosh were 
used. The mean values are given with standard error of means. In study I, the differences 
between the study groups and controls were tested by applying t-test, Fisher’s exact test and 
the nonparametric Mann-Whitney U test. The association between various parameters was 
assessed by logistic regression analysis employing an odds ratio with the 95 % confidence 
interval. In study II, the differences between the subjects were tested by applying the Chi-
square test. The level of significance was ≤ 0.05 in all analyses.  
 
 
 
 
 
 
 
 
5 Results  
Key results from studies I-IV. The logistics of the study are described in figure 4.  
 
 
 
 
 
 
  
 
 
Study I. Evaluation of medical and autopsy records of the cases (n=150) with an 
ischemic lesion. A control group of 185 subjects without any hippocampal 
ischemic lesions was included.
The prevalence of hippocampal infarcts (i.e. type 1 or 2 lesions) was 12%, 
increasing to 13% when subjects with cognitive impairment were included. 
Large hemispheric brain infarcts were strongly associated with cardiovascular 
risk factors. Hippocampal infarcts displayed a significant association only 
with large hemispheric brain infarcts, heart failure and higher cardiovascular 
index (CVI) as assessed post-mortem. 
Study II. Evaluation of TDP43 pathology and neuropathological diagnosis of 
the cases (n=250). 
18% of all cases and 43% of the subjects with a hippocampal pathology which 
was other than vascular in origin displayed hippocampal TDP43-pathology, 
increasing to 60% in subjects with concomitant Alzheimer’s disease and α-
synuclein pathology.  
Study III. Inter-rater study and joint meeting with all 260 cases (+IHC stains) 
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Figure 5.  
 
5.1 DEMOGRAPHICS OF THE COHORT  
The mean age of the subjects (n=251) showing a hippocampal alteration was 77±4 S.E years 
with a range from 7 months to 97 years. The demographics with regard to the different lesion 
types are given in table 3. The mean brain weight was 1,300 ±12 grams (S.E) and the post-
mortem delay was 68 ± 3 hours (S.E). Fifty-nine percent of the subjects with a hippocampal 
alteration were female and 41 % were male.  
5.2 PREVALENCE OF HIPPOCAMPAL LESIONS  
A hippocampal lesion was detected in 18 % of the 1388 cases for whom there was a 
representative hippocampal sample. The most common lesion type observed by the 
coordinating group prior to the joint meeting was type 1 with 143 cases. This was followed 
by type 3 (n=59), type 4 (n=27), type 2 (n=13) and type + (n=9).  
Five patterns of degenerative or vascular lesions were identified from the 
autopsy cohort of 1,388 subjects. Agreement rate was 36%-70%; the highest 
values for vascular lesions. Agreement in assigning the diagnosis of HS varied 
from 0% to 86%. Recommendations for using the term “HS” were given. 
    Study IV. Clinicopathological findings in 30 subjects with HS, i.e. type 4 lesion  
The clinicopathological spectrum is very heterogenous. AD related pathology 
was seen in 22 subjects and TDP43 pathology in 17 subjects. Five subjects had 
epilepsy. 
 
 
 
5.3 CLINICAL MANIFESTATIONS  
The clinical manifestations (history of seizures and cognitive impairment) are given in table 
3. The most common mode of death was “slow death over a period of more than 24 hours” 
(54%), followed by “death within 24 hours without evidence of cerebral hypoxia (27%).  
Table 3 
Initial type n Age Sex (m/f) BW CI % EP % 
No lesion 9 77±3 3/6 1,318±77 33 10 
+ 9 69±6 2/7 1,299±57 33 10 
1 143 77±1 67/76 1,343±12 26 4 (NA 4) 
2 13 76±1 7/6 1,329±59 31 23 (NA 8) 
3 59 77±1 18/41 1,260±24 71 7 (NA 3) 
4 27 78±4 10/17 1,137±51 74 11 
All 260 77±1 107/153 1,300±12 7 4 
       
n – number, Age – mean age at death (S.E.), BW – brain weight in grams (S.E.), CI – cognitive 
impairment, EP – epilepsy, NA – not available 
5.4 INTER-RATER TRIAL.  
The agreement percentages are summarized in table 4. The overall agreement rate in the 
inter-rater trial was 48 %. This increased to 59% when the nine control cases, i.e. cases lacking 
a lesion, were excluded. The participants did not have access to any other information other 
than the H&E-stained section and the age of the case. The highest agreement rate was reached 
for the type 1 lesions and the lowest, 50 %, for the type 3 lesions. The cases with no lesion 
achieved an agreement rate of only 36 %. The agreement rate on the diagnosis of HS for the 
cases was 86 % for type 4, 44 % for type 3, 42 % for type 2, 14 % for type + and 1 % for type 1. 
Five out of the 9 controls were given the type + or type 3 as the additional stains revealed 
pathological findings easily missed in H&E. Similarly five of 59 type 3 cases were reassigned 
either to type + (1 case) or type 4 (4 cases).  With respect to the remaining 250 cases (96%), the 
independent participants agreed with the coordinating group.  
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Table 4 Inter-rater study 
 
Type given by the 
coordinating group No lesions Type +  Type 1 Type 2 Type3 Type 4 
No lesion 36 19 19 - 17 6 
+ 8 44 15 8 19 6 
1 9 4 70 7 4 3 
2 - 8 2 67 - 19 
3 2 5 12 10 50 22 
4 1 2 - 25 3 51 
5.5 HIPPOCAMPAL SCLEROSIS IN THE INTER-RATER TRIAL  
The highest agreement rate regarding the designation of HS was 100 % for the control cases 
and the lowest was 42% for the type 2 cases. The agreement rate was 86% for the type 4 
lesions, 44% of type 3 lesion, 42% of type 2 lesions and 14% of type + lesions and 1% of the 
type 1 lesions. Thirteen of the 85 cases that were assigned as type 3 or 4 lacked 
neurodegenerative pathology assessed here, i.e. non-TDP43-, p62-, HPtau-, and/or alpha-
syn-associated pathology). These 13 cases with other yet-unknown neurodegenerative or 
vascular pathology yielded a poor agreement for assigning a pathological alteration as HS.  
 
Table 5  
 
Final type N 
Agreement 
% TDP43 
p62 
(GCL/CA) 
HPtau 
(GCL/CA) αS 
No lesion 4 36 1 1/7 3/7 0 
+ 15 44 0 1/4 2/5 0 
1 143 70 4 13/92 14/102 1 
2 13 67 1 2/4 1/6 0 
3 54 50 24 41/50 34/51 4 
4 31 51 15 16/7 10/17 0 
All 260 48 45 74/164 64/188 5 
       
5.6 THE JOINT MEETING USING A MULTI-HEAD MICROSCOPE 
During the joint meeting, 10 of the 260 cases were reassigned to a group different from that 
originally assigned by the coordinating group (table 5). Five (55%) of 9 controls were 
reassessed as type + or type 3 due to pathological findings revealed by IHC. Five (8%) of 59 
type 3 cases were reassigned either to type + or type 4 (4 cases). In the remaining 250 cases 
(96%), the independent neuropathologists agreed with the original assignment given by the 
coordinating group. The type 4 pathology defined here resembles the lesion originally 
defined by Sommer as HS (Sommer W 1880). During the discussion, some of the participating 
neuropathologists admitted that they might have missed some of the type 1 lesions as well 
as some of the pathology present in the type + lesions.  
 
 
 
 
 
Figure 6 (adapted from study III) Lesion types illustrated.  
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5.7 HIPPOCAMPAL LESIONS AND VASCULAR DISEASES 
A hippocampal infarct, i.e. a type 1 or 2 lesion, was seen in 12% of the subjects. From the 260 
cases included in the inter-rater study, 60% were vascular lesions. The mean age at death of 
these subjects was 79±1 years and 75±1 years in the control group (i.e. subjects autopsied in 
2003 lacking a hippocampal infarct, n=96). Clinical data were available for 116 subjects. The 
agreement rate for hippocampal infarcts in the inter-rater study was 76%. There were no 
statistically significant differences with respect to gender or brain weight between these 
groups. Out of the 1,245 subjects, 311 (25%) had shown signs of cognitive impairment during 
their life. Forty (13%) of these subjects displayed evidence of a hippocampal infarct. Heart 
failure was significantly (p < 0.05) more common in subjects with a hippocampal infarct 
compared to the control group (29% vs. 16%). The prevalence of stroke was significantly 
higher (p < 0.05) in subjects with the hippocampal infarct compared with controls (29% vs. 
16%) and this difference was highest in the youngest group, i.e. 54-65 years of age, (44% vs. 
5%). The oldest age group, i.e. 81-95 years of age, did not display a statistically significant 
difference in the prevalence of stroke. There were no statistically significant differences when 
the prevalences of peripheral artery disease in the lower extremities, coronary disease, 
myocardial infarct, atrial fibrillation, transient ischemic attacks, and diabetes mellitus were 
compared.  
  
There were no statistically significant differences in the analysis of either the primary arterial 
distribution or the hemispheric localization of the gross infarcts. In addition, the number and 
distribution of “watershed” infarcts did not differ significantly between the groups. The 
neuropathologically verified gross infarcts were less commonly multiple in subjects without 
hippocampal infarcts (26% vs. 37%). In subjects with a clinical diagnosis of stroke (n=49) the 
following prevalences were noted for these cardiovascular diseases; hypertension - 45%; 
peripheral artery disease in the lower extremities - 8%; coronary artery disease - 35%;  
myocardial infarct - 20%; atrial fibrillation- 20% and heart failure - 18%.  The corresponding 
prevalences of these diseases were 43% (hypertension), 6% (peripheral artery disease in the 
lower extremities), 32% (coronary artery disease), 22% (myocardial infarct), 20% (atrial 
fibrillation) and 20% (heart failure) in subjects with a neuropathologically verified gross 
cerebral infarct (n=65).  The prevalence of lacunar state changes in the basal ganglia was not 
statistically significantly different between the groups. There were no statistically significant 
differences in the AD related HPtau stages between the groups.  
 
Cognitive impairment was present in five out of the nine of the subjects with a large cystic 
infarct, i.e. type 2 lesions, whereas 38 out of the 107 subjects with a small infarct, i.e. a type 1 
lesion had displayed evidence of cognitive impairment. There were no significant differences 
in the presence of αS, Aβ and CAA in subjects with or without a hippocampal infarct. The 
CVI was significantly p < 0.01) higher (9.3 ± 0.2 vs. 8.4 ± 0.3) in subjects with hippocampal 
infact compared to the control group. The prevalences of gross and microscopic infarcts 
outside the hippocampus were significantly (p < 0.01 and p < 0.05) higher in subjects with a 
hippocampal infarct (40% vs. 20% and 49% vs. 34%).  
 
 
 
 
Logistic regression analysis which included the confounding cardiocerebrovascular factors 
and age at death was conducted in study I; it revealed that the age at death was significantly 
higher in subjects with a hippocampal infarct compared to those without (p = 0.04).  
5.8 EPILEPSY AND CLINICOPATHOLOGICAL FINDINGS IN STUDY IV 
The overall prevalence of EP in this study cohort was 4 %. EP was present in one subject in 
the control group, three subjects with a type 1 lesion, two subjects with type 2 lesions, three 
subjects with a type 3 lesion and in five subjects with a type 4 lesion. In 4% of the type 1 cases, 
the information regarding EP was not accessible or reliable. The corresponding percentages 
of unavailable/unreliable were type 2 lesions – 8%; three for type 3 lesions – 3% and type 4 
lesions – 11%. Granule cell dispersion, which is a common finding in surgically resected 
hippocampi, was not present in any cases of the present material. Three of the five subjects 
with EP were female. The mean brain weight was 1250±49 grams and the mean age at death 
was 67±4 years. Cognitive impairment was present in four of these cases (31%).  
 
Study IV included subjects with a type 4 lesion (n=30, one pediatric subject excluded). The 
clinicopathological findings are summarized in table 6. In this group, the most common cause 
of death was pneumonia (n=8), followed by infection /sepsis (n=6), cardiac insufficiency 
(n=6), cardiac infarction (n=3), central nervous system infarction (n=4), neoplasia (n=2) and 
pulmonary embolism (n=1).  
 
Seven of the subjects with a type 4 lesion were cognitively unimpaired and displayed mild 
AD related pathology, i.e. primary age related tauopathy (PART) or vascular alterations. 
TDP43 was not present in any of these subjects. Two out of the seven (21%) subjects with HS 
of unknown origin, or “pure HS” had evidence of EP in their medical records; these revealed 
a complicated medical history. Twenty-three out of the 30 subjects had cognitive 
impairments and the primary cause for this was assessed as AD in eight subjects, FTLD-TDP 
in five subjects, DLB in two subjects, and vascular brain alterations in five cases. 
Neuropsychiatric disorders had been present in three subjects. In one subject, mild AD 
related pathology with concomitant TDP43 pathology was seen, and the medical records 
revealed a history of a severe head trauma. In two subjects, only mild AD related pathology 
could be observed, one of these had a history of a cardiac infarct resulting in cardiac 
insuffiency and the other was clinically diagnosed as having a late-onset psychosis. 
Concomitant pathology in the form of AD with DLB or TDP43 or vascular pathology was 
detected in 13 out of 23 cognitively impaired subjects. Hippocampal TDP43 pathology as 
seen in 13 out of 23 cognitively impaired subjects. Hippocampal TDP43 pathology was 
present in seven out of eight (88%) subjects with primary AD, in one out of two (50%) subjects 
with primary DLB and in three out of five (60%) subjects with primary vascular alteration. 
Three of the cases with CI had a clinical history of EP and one of these cases with EP fulfilled 
the clinicopathological criteria for AD. Two cases with dementia and EP displayed evidence 
of extensive vascular lesions and concomitant AD related pathology. Five cases exhibited 
neuropathological findings consistent with FTLD-TDP43.  
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AD related pathology, i.e. primary age related tauopathy (PART) or vascular alterations. 
TDP43 was not present in any of these subjects. Two out of the seven (21%) subjects with HS 
of unknown origin, or “pure HS” had evidence of EP in their medical records; these revealed 
a complicated medical history. Twenty-three out of the 30 subjects had cognitive 
impairments and the primary cause for this was assessed as AD in eight subjects, FTLD-TDP 
in five subjects, DLB in two subjects, and vascular brain alterations in five cases. 
Neuropsychiatric disorders had been present in three subjects. In one subject, mild AD 
related pathology with concomitant TDP43 pathology was seen, and the medical records 
revealed a history of a severe head trauma. In two subjects, only mild AD related pathology 
could be observed, one of these had a history of a cardiac infarct resulting in cardiac 
insuffiency and the other was clinically diagnosed as having a late-onset psychosis. 
Concomitant pathology in the form of AD with DLB or TDP43 or vascular pathology was 
detected in 13 out of 23 cognitively impaired subjects. Hippocampal TDP43 pathology as 
seen in 13 out of 23 cognitively impaired subjects. Hippocampal TDP43 pathology was 
present in seven out of eight (88%) subjects with primary AD, in one out of two (50%) subjects 
with primary DLB and in three out of five (60%) subjects with primary vascular alteration. 
Three of the cases with CI had a clinical history of EP and one of these cases with EP fulfilled 
the clinicopathological criteria for AD. Two cases with dementia and EP displayed evidence 
of extensive vascular lesions and concomitant AD related pathology. Five cases exhibited 
neuropathological findings consistent with FTLD-TDP43.  
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Clinically two of the cases studied thoroughly for study IV had a complicated medical history 
without any remarkable neurodegeneration. One case had clinical AD with seizures several 
times a year and the neuropathological finding was AD Braak VI with HS. One case had 
multiple old cerebral infarcts, cerebral amyloid angiopathy and AD Braak III and one case 
had multiple old cerebral infarcts and PART (Braak I).  
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5.9 HIPPOCAMPAL LESIONS AND AD-RELATED PATHOLOGY  
The mean age of subjects with AD-related lesions (n = 38 in study II) was 82± 1 being 
significantly higher (p < 0.05) when compared to the subjects lacking AD-related pathology 
(n = 212, 77±1 years). The mean age at death of the subjects with concomitant AD-related 
pathology with concomitant TDP43-pathology (n=20, 85± 2 years) was significantly higher (p 
< 0.05) higher when compared with those subjects with only AD-related pathology (n = 18, 
80± 1 years). αS pathology was detected in only 2% of the cases. 
5.10 TRANS ACTIVE RESPONSE DNA BINDING PROTEIN 43 PATHOLOGY 
AND HIPPOCAMPAL LESIONS  
In study II, p62 was used to screen the hippocampi for neurodegenerative pathology. 
Hippocampal TDP43-pathology was assessed in the granule cell layer and the CA regions of 
the hippocampus. P62-immunoreactive inclusions were present in 29% and 62% of these 
were TDP43-positive. When subdivided according to the type of hippocampal pathology, i.e. 
vascular or some form other than vascular pathology, TDP43-IR lesions were seen in 5/156 
(3%) subjects with vascular lesions and in 33/94 (35%) subjects with some lesion other than 
one which would be vascular in origin. TDP43-IR lesions were more often seen in subjects 
with severe AD pathology whereas no similar association was present in cases exhibiting 
alpha-synuclein. In subjects with severe tauopathy (i.e. Braak stages V-VI) and concomitant 
alpha-synuclein pathology (Braak stages V-VI), TDP43-pathology was seen in 3/5 subjects 
compared with 10/24 in the group of subjects with only tauopathy (Braak V). TDP43-
pathology was not detected in subjects with a diagnosis of amyotrophic lateral sclerosis 
(ALS), spinocerebellar ataxia (SCA), AgD or PSP. In contrast, TDP43-pathology was seen in 
all subjects with a diagnosis of FTLD-TDP43 (n=5). Both p62 and TDP43 positive inclusions 
were observed significantly more often in cognitively impaired subjects in comparison to 
cognitively unimpaired subjects (35% vs. 6%, p ≤ 0.001). 
  
P62 and HPtau pathology dominated in the CA1 region when compared with the GCL in 
subjects both with and without CI, whereas TDP43 pathology was seen in the GCL. TDP43-
pathology was observed in 43% of the subjects with a pathology which was other than 
vascular in origin and even more often in the subgroup of these with CI (51%). In the lesion 
types defined in study III, TDP43-pathology was present in one case from the control group, 
four cases with type I lesions (i.e. vascular), one case with a type II lesion (i.e. large cystic 
infarct as the primary lesions), 24 cases with the type 3 lesions and 15 of those with type 4 
lesions. TDP43 pathology was seen in 43% of the subjects with a non-vascular pathology and 
even more often in the subgroup of these with CI, 51%.  
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6 Discussion  
The main aims(s) of the present series of studies was to investigate the prevalence of 
hippocampal lesions in an elderly unselected population, to correlate the findings with 
common neurodegenerative diseases as well as in epilepsy. The main novel findings were 
the determination of the prevalence of hippocampal lesions in a large non-selected cohort 
and the neuropathological consensus recommendations for assessing post mortem 
hippocampal alterations. While clearly more research is warranted, these present findings 
help to clarify the pathophysiology of neurodegenerative diseases. On the basis of a better 
understanding of the molecular and cellular level events, new avenues for more targeted 
treatment options can be expected in the future.  
6.1. THE STRENGTHS AND LIMITATIONS OF THE STUDY 
This series of studies has several strengths. Previously it has been demonstrated that the 
prevalence of neurodegenerative pathology is significantly influenced by the selection of 
cases (Parkkinen et al. 2001). The source of recruitment of the subjects ranging from a highly 
specialized tertiary clinical research center to a nursing home or a community brain bank 
may lead to a selection bias and affect the frequency of different diagnoses in a cohort. 
Enrollment in a brain bank has been shown to be affected by factors such as ethnicity and 
higher education (Fillenbaum et al. 1996). In order to control the selection bias, the strategy 
applied here was to select a high number of consecutive cases regardless of the clinical 
phenotype and then to screen the sections blindly to any clinical or demographical 
information. In addition, the cohort included subjects from a university hospital, community 
health centers and hospitals as well as forensic cases. There were also a number of pediatric 
cases. Thus this material is significantly different from the material examined in previous 
studies and the number of subjects is very large. The age range was from seven months to 97 
years, thus representing the whole lifespan. Nonetheless, as the cohort consisted of subjects 
that had undergone an autopsy with a neuropathological examination it did not represent 
general population, but may be considered to mirror it to some extent. All of the brains were 
macro- and microscopically evaluated by one experienced neuropathologist following a 
standardized protocol. With these strategic precautions it was possible to avoid, at least to 
some extent, a common problem leading to erroneous conclusions. 
 
The present series of studies suffers from some limitations due to methodological issues. 
When compared to animal studies, human material is more variable due to many 
uncontrollable factors such as genetic variation, medications used, surgical procedures, 
environmental factors, systemic diseases and post-mortem delay, all of which can affect the 
quality of the tissue. The human brain displays major anatomic variations between 
individuals compared to that in laboratory mice with controlled genetic background. When 
using post-mortem tissue, one has to be aware of the effect of post-mortem delay, i.e. the time 
interval between death and autopsy. Post-mortem events such as autolysis and fixation time 
of the samples may have an impact on the immunohistochemical staining results. It has, 
 
 
however, been reported that variations in post-mortem delay exert no qualitative effect on 
the staining patterns  (Kuusisto, Parkkinen & Alafuzoff 2003a). For example, good Aβ IR 
quality can be obtained even after 14 years of fixation  (Pikkarainen, Martikainen & Alafuzoff 
2010). In these experiments, all of the IHC stainings were conducted manually, the staining 
protocols were standardized and positive controls were always included. The antibodies 
have been well characterized and are widely used commercial antibodies and thus can be 
considered as reliable. In the present material, the mean post-mortem delay was more than 
60 hours. However, this was inevitable due to logistical factors. 
 
The cohort used in this study represents mostly the eastern Finnish population, in which the 
genetic variation is smaller than in many other populations. For the majority of the cases, 
adequate clinical information was available, but in some subjects, especially in the forensic 
cohort, this was not always the case. Therefore, some subjects classified as being cognitively 
intact might in fact have displayed mild cognitive impairment that had not been recognized 
during their lifetime. Similarly, the clinical information was not available in some cases, 
especially in the forensic cohort. However, it is unlikely that the presence of moderate or full-
blown dementia would have been overlooked. The clinical information was analyzed and 
interpreted by a neurologist only in study IV and thus studies I, II and III lack the expert 
input from this kind of specialized clinician. The IHC stainings were assessed 
semiquantitatively, which may be less precise than morphometric techniques, for example 
counting the number of affected neurons per area. Neuropathology is a highly visual medical 
discipline and thus prone to intra- and interobservational variability. It is common to arrange 
inter-rater studies and workshops to devise reproducible guidelines in attempts to reduce 
this variability. Another drawback in the present study is the lack of genetic information. 
During recent years, numerous studies have focussed on the genetics of HS.  
 
The cardiovascular index (CVI) used in study I is a rough estimate of the cardiovascular 
burden and different variables, such as cerebrovascular atherosclerosis or cardiac pathology 
were not analyzed independently.  Microscopic infarcts, as defined in pathology, are visible 
only under the microscope and due to the fact that in the standardized neuropathological 
sampling protocol, 16 brain regions were routinely sampled, it is possible that some of the 
microinfarcts could have been missed; this is inevitable as sampling and serially cutting the 
whole brain would have been an enormous task.   
 
Another limitation is that the hippocampus was sampled only from one hemisphere, 
routinely from the left, if both sides were macroscopically identical. This is a common 
approach in neuropathology as more extensive sampling would increase costs, laboratory 
workload and require more space since the number of samples would be much higher. HS 
in the elderly may be unilateral in 40-55% of the cases (Nelson et al. 2011b, Zarow et al. 2012a). 
However, it is unlikely that this would have affected the results as HS is macroscopically 
visible in most cases and in general, both hippocampi were sampled if there were clear 
macroscopical signs of atrophy.   
 
Microinfarcts, or type 1 lesions according to the devised guidelines, are in most cases not 
macroscopically visible and thus some of them may have been missed. In future studies, the 
sampling protocol should involve both of the hemispheres and furthermore it may be better 
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inter-rater studies and workshops to devise reproducible guidelines in attempts to reduce 
this variability. Another drawback in the present study is the lack of genetic information. 
During recent years, numerous studies have focussed on the genetics of HS.  
 
The cardiovascular index (CVI) used in study I is a rough estimate of the cardiovascular 
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were not analyzed independently.  Microscopic infarcts, as defined in pathology, are visible 
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sampling protocol, 16 brain regions were routinely sampled, it is possible that some of the 
microinfarcts could have been missed; this is inevitable as sampling and serially cutting the 
whole brain would have been an enormous task.   
 
Another limitation is that the hippocampus was sampled only from one hemisphere, 
routinely from the left, if both sides were macroscopically identical. This is a common 
approach in neuropathology as more extensive sampling would increase costs, laboratory 
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visible in most cases and in general, both hippocampi were sampled if there were clear 
macroscopical signs of atrophy.   
 
Microinfarcts, or type 1 lesions according to the devised guidelines, are in most cases not 
macroscopically visible and thus some of them may have been missed. In future studies, the 
sampling protocol should involve both of the hemispheres and furthermore it may be better 
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to take serial sections of the whole hippocampus in order to identify all of the lesions. In 
addition, neither the extent nor stage of the hippocampal TDP43-pathology was evaluated. 
The IHC stainings were assessed semiquantitavely, which may be less precise than 
assessment by morphometric techniques, i.e. counting the number of affected neurons per 
area or by applying other objective techniques. There were no subjects with TLE in this cohort 
and thus it was not possible to classify the HS lesions according to the new guideline 
introduced by the International League Agaist Epilepsy (Blumcke et al. 2013). 
 
There is a need for good stains suitable for screening the different neurogenerative lesions 
before staining with HPtau, alpha-syn or TDP43, for example. Here, p62 was used for 
screening and the use of p62 can be recommended.  However, one must be aware that not all 
lesions, such as pretangles and grainly alpha-syn aggregates are p62-positive as reported by 
Kuusisto and coworkers  (Kuusisto, Parkkinen & Alafuzoff 2003) and in these cases, 
additional stains are required. 
6.2 INTER-RATER STUDY  
The hippocampus is a brain structure assessed by neuropathologists almost on a daily basis. 
Nonetheless, as far as is known, the assessment of hippocampal pathology has not previously 
been subjected to an analysis of inter-rater agreement and stringent detailed definitions of 
hippocampal pathologies have not been devised. One of the primary objectives of this thesis 
was to create reproducible guidelines for the neuropathological assessment of hippocampal 
lesions. Neuropathology is a sub-speciality covering many different fields from 
neurodevelopmental to vascular diseases as well as from tumours to neurodegeneration. 
Hippocampal sclerosis is a lesion encountered by the epilepsy-oriented neuropathologists as 
well as neuropathologists focusing on neurodegenerative disease. There has, however, been 
confusion on the use of terminology and thus it was deemed important to undertake the 
present study. During the selection process and screening of the large autopsy material, it 
became obvious that there were different types of lesions affecting different parts of the 
hippocampal formation and after the initial screening and selection of the cases, it did appear 
that there were as many as twelve different groups and subgroups! It was realized that this 
would lead to even more confusion instead of clarity and reproducibility. Thus several 
groups were combined so that ultimately there were five different groups as defined in study 
III.  
 
The highest agreement rate, 70%, which can be considered as good, was achieved for the type 
1 lesions. This is not surprising as these were often relatively easy to find in H&E stained 
sections. However, some of these lesions were very small and the participating 
neuropathologists admitted that they were missed in some cases. Furthermore, the pathology 
in some of the type + cases was rather modest and these were frequently assigned to the 
control category, explaining the low agreement rate.  
 
The overall agreement rate in the inter-rater study was 48%. During the joint meeting (part 
of study III) discussions took place and reasons for the low rate became understandable. 
During these discussions around the multi-headed microscope with the additional IHC 
 
 
stained sections available for all cases, it was concluded that many neurodegenerative 
lesions, such as neurofibrillary tangles or Lewy bodies were frequently missed in H&E 
stained sections, particularly in the cases in which they were sparse. In addition, TDP43-
positive inclusions are relatively common in the elderly and these were not observed with 
the H&E stain. 
 
After the debates and discussions, the final agreement rate after the meeting was 96% with 
the pathology type assigned originally by the coordinating group. Thus a high agreement 
rate can be achieved when assessing hippocampal alterations by adhering to the instructions 
given in study III. Based on these discussions, it was concluded that IHC should always be 
included when assessing hippocampal pathology, particularly in those cases with a 
suspected neurodegenerative pathology. 
6.3 TERMINOLOGY  
One of the aims of this study was to clarify the use of the term “hippocampal sclerosis” in 
neuropathology. A common definition of HS occurring in the relevant literature is “selective 
neuronal loss and gliosis in the CA1 sector and the subiculum” (Jellinger 1994). However, as 
demonstrated in the review section of this thesis, there is variability in the definitions used 
and this has to be taken into account when comparing different studies.  
 
In the inter-rater study, as many as 42% of the cases with a type 2 hippocampal lesion, which 
contained cystic infarcts, were assigned as representing “HS” by the participating 
neuropathologists. This was unexpected and rather surprising. During the joint meeting, the 
participants debated the use of the term “HS” and it was agreed that type 1 and 2 lesions, 
which arise due to the occurrence of an infarct, should not be called HS. However, there is a 
possibility that the type 2 lesions may develop into a HS type lesion in some individuals. HS 
has been demonstrated to occur after an ischemic event (Volpe, Petito 1985) and there has 
been reports of increased prevalence of cardio- and cerebrovascular disease in subjects with 
HS  (Corey-Bloom et al. 1997, Ala, Beh & Frey 2000, Beach et al. 2003, Marshall et al. 2005, 
Attems, Jellinger 2006, Neltner et al. 2014b).  
 
Alterations of type 3 and 4 can be referred to as “HS”, but the severity of the overall 
degenerative change should be taken into account. The general agreement was that the term 
“HS” should be reserved for cases with severe pathology with either total or subtotal loss of 
CA neurons and an appreciable loss of volume in either the presence or the absence of 
neurodegenerative pathology. It is important to define the underlying mechanism leading to 
the marked cell loss and gliosis in the CA subfields. Thus, it is recommended that type 3 or 4 
alterations with HPtau pathology should be referred to as “HS in association with HPtau 
pathology” and the type 4 alteration with TDP-43 pathology should be referred to as “HS in 
association with FTD-TDP- pathology”. The type 4 alterations lacking TDP43, HPtau, αS, 
fused in sarcoma-pathology may be referred to as “HS lacking known neurodegenerative 
markers”.  
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It is recommended that the term “HS” should be used when the lesion is encountered in 
elderly subjects in the absence of a long-standing history of epilepsy, whereas the term 
“mesial termporal sclerosis” should be applied when the lesion is encountered in subjects 
with temporal lobe epilepsy.  
 
HS is relatively often observed in the elderly at neuropathological examination. The reported 
prevalence in autopsy cohorts presenting with dementia varies from 2.8% to 13% (Amador-
Ortiz, Dickson 2008). In the present unselected material of 1388 subjects, with type 3 and type 
4 being referred to as HS, the prevalence of HS was 6%, which is comparable to previous 
reports. The term HS-aging was introduced into medical literature mainly during the 
maturation process of this thesis. There is some overlap in the terminology and older 
publications referring to HS-aging should be interpreted with caution. The term “HS-aging” 
has been postulated to be used in elderly cases, i.e. subjects older than  80 years of age who 
display evidence of HS, in other words if the extent of HS is very striking and the AD changes 
rather modest, then this condition can be designated as “HS-aging” (Nelson et al. 2013). 
   
In the present cohort, some of the oldest subjects with type 3 or type 4 hippocampal lesions 
may be attributed to HS-aging. When compared to other studies on HS-aging, the present 
material was heterogenous and also younger subjects were included. The youngest subject 
with a full-blown type 4 lesion in our cohort was less than one year of age. The average age 
of the subjects evaluated here was below 80 whereas the prevalence of HS-aging is highest 
in subjects over the age of 80. HS is generally accepted as a common finding in subjects with 
FTLD, especially FTD-TDP. In some dementia cases, HS is the only finding and this is often 
referred to as “pure HS”. One possibility is that in these cases, the dysfunctional protein is 
still to be discovered.  
6.4 ISCHEMIC LESIONS 
It was hypothesized that since the hippocampus is a particularly vulnerable brain region, 
infarcts in this region could well be associated to cardiovascular morbidity. The aim of study 
I was to investigate the prevalence of hippocampal infarcts, i.e. type 1 and 2 vascular lesions 
in the large material including subjects with or without cognitive impairment and to correlate 
these findings with the clinical data on cardio- and cerebrovascular disease as well as with 
other clinical comorbid variables. The novel finding from this study was that the prevalence 
of a hippocampal infarct, according to our definition, was 12% in an unselected large post-
mortem material. The prevalence of these lesions in general population is not known.  
As far as is known, this is the first study in which these lesions have been assessed in an 
unselected cohort. Hippocampal microinfarcts have been reported previously in as many as 
44% of subjects with both AD and cerebral infarcts (Del Ser et al. 2005) and more than 50% of 
subjects with ischemic vascular dementia showed evidence of a hippocampal injury (Vinters 
et al. 2000). In this cohort, hippocampal infarcts were observed to be common in subjects with 
both clinical stroke and grossly apparent hemispheric infarcts. This may be caused by 
alterations in the circulation and secondarily by the increase of pressure in the uncal area in 
which the hippocampus is located. An association was detected between heart failure and 
hippocampal infarcts, but no statistically significant difference was noted between 
 
 
hippocampal infarcts and cardiovascular risk factors such as hypertension, peripheral artery 
disease in the lower extremities, atrial fibrillation, and myocardial infarct. This finding has 
been supported by another study (Neltner et al. 2014a). In contrast, it was found that the 
cardiovascular index, used as a post-mortem estimate of the general cardiovascular 
morbidity, was significantly higher in subjects with hippocampal infarcts. In the study of 
Dickson and coworkers, a relatively high number of the cases with HS had the diagnosis of 
arteriolosclerosis, i.e. thickening of the small blood vessels, compared to controls (Dickson et 
al.1994). Furthermore, HS with comorbid AD pathology is often encountered in subjects with 
coronary atherosclerosis, but “pure” HS is rare in older subjects who frequently have 
comorbid pathologies (Jellinger 2000). However, in a large longitudinal study, HS-aging in 
the elderly was not associated with an increased prevalence of hypertension, transient 
ischaemic attacks, or smoking (Nelson et al. 2011b), but in that study, either large or lacunar 
infarcts elsewhere did elevate the risk for HS pathology. Hippocampal hypoxic-ischemic 
injury may result in two types of alterations; either in the form of a classic microinfarct with 
cavication, foamy macrophages and capillary proliferation or as neuronal dropout without 
any remarkable cavitation histologically resembling HS as seen in FTLD or TLE (Leifer, 
Kowall 1993, Taraszewska et al. 2002). In the post-mortem study of Hatanpaa and coworkers, 
it was shown that hypoxic-ischemic lesions most commonly affected the proximal and 
middle parts of the CA1 (Hatanpaa et al. 2014). In the present study, the regions affected by 
type 1 (or smaller type 2 lesions in some cases) lesions were not analyzed and thus this 
finding cannot be verified. 
6.5 TDP43 AND HIPPOCAMPAL LESIONS  
During the last ten years, TDP43 has attracted enormous scientific interest. TDP43 pathology 
was initially described in subjects with FTLD as all of the subjects with the diagnosis of FTLD 
displayed TDP43-pathology. Later studies have shown TDP43-pathology to be present in a 
wide variety of pathological conditions, mainly in neurodegenerative diseases, and it is 
detectable in as many as 90% of HS cases (Nelson et al. 2011b, Pao et al. 2011). 
 
In the present material, TDP43 pathology was detected in only 3% of cases with a 
hippocampal vascular alteration, i.e. lesion types 1 and 2. Most of these cases had 
concomitant neurodegenerative pathology. This is in line with the findings emerging from 
the study of Lee and coworkers (Lee et al. 2008a) in which TDP-43 pathology was not seen in 
ischemic conditions. In contrast, 35% of the subjects in which the lesion was other than 
vascular in origin, i.e. types 3 and 4, demonstrated TDP43-pathology. Here, TDP43 pathology 
was observed in 6% of the cognitively unimpaired subjects, which is comparable to previous 
reports (Nakashima-Yasuda et al. 2007b, Hatanpaa et al. 2008), but significantly lower than 
in the recent longitudinally tracked population-based study of Keage and coworkers (Keage 
et al. 2014),  in which TDP43 was present in 18% of the elderly cases with dementia and in 
35% of the cases with clinical dementia. Furthermore, the subjects with TDP43 pathology 
were older (>90 years) at death compared to those without TDP43 pathology (Keage et al. 
2014b). In the very recent study of Uchino and coworkers, TDP43 IR structures were seen in 
as many as 40% of control elderly cases with pathologically minimal senile changes (Uchino 
et al. 2015). 
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In study II, subjects with a hippocampal lesion were screened for hippocampal TDP43-
pathology. Based on these findings, it can be concluded that when hippocampal pathology 
is seen in conventionally stained preparations, TDP43-pathology can be expected in almost 
one fifth of the cases and if the subject had CI, the odds are elevated to one in three. With 
severe concomitant AD-pathology, the prevalence of TDP43 was increased up to almost ever 
second case. Thus, this finding is comparable to previous studies in which TDP43 
proteinopathy has been shown to be common in subjects with AD, with reported prevalences 
ranging from 19% to 57% (Amador-Ortiz et al. 2007a, Uryu et al. 2008, Arai et al. 2009,  Bigio 
et al. 2010, Davidson et al. 2011). In addition, in the present series, the prevalence of TDP43-
pathology increased to 55% in subjects with concomitant AD and αS pathology, which is in 
line with previous observations (Nakashima-Yasuda et al. 2007). Here, the number of subjects 
with concomitant pathology was small and thus studies with larger sample sizes are 
indicated. Thus the accumulation of TDP43 might be related to normal aging and the 
pathological load was shown to increase with age similarly to AD-related pathology. TDP43 
pathology was seen in combination with late stage AD in 46% of the subjects; this is a higher 
percentage than in some previous reports. (Amador-Ortiz et al. 2007b, Higashi et al. 2007, 
Josephs et al. 2008), but similar prevalences have also been reported (Arai et al. 2009).  
 
The role of TDP43 pathology with hippocampal lesions still remains open. The present study 
also found that the subjects with AD and concomitant TDP43-pathology were significantly 
older than subjects with only AD-related pathology, a result reported previously (Duyckaerts 
2015). One explanation for this finding is that AD with TDP43 pathology represents a 
separate subgroup with different neurodegenerative mechanisms.  
6.6 EPILEPSY 
HS was initially described in the 19th century in association with temporal lobe EP. HS is a 
common finding in surgically resected tissue in patients with refractory temporal lobe 
epilepsy. Thus it was logical to assess whether the present material included subjects with 
EP. The overall prevalence of EP in the material was 4%. It is not possible to make any valid 
comparison of this value with previous studies due to selection strategy applied here. The 
material did not include subjects with classical mesial temporal lobe EP with HS.  These 
patients are mainly from the younger part of the population and are often referred to EP 
surgery in order to attempt to control their seizures. Epileptic seizures and AD has attracted 
more scientific attention during the recent years. The clinicopathological spectrum of the 
subjects with EP in the present study was very heterogenous and the number was relatively 
small. Epilepsy can be caused by various etiologies, including genetic defects, tumors, 
cortical dysplasia, or infarcts. Post-mortem studies on subjects with EP are not numerous and 
there is very limited information about the neuropathological findings in elderly subjects 
with EP with or without a neurodegenerative disorder. In addition, in many of the 
epidemiological studies assessing EP in subjects with AD, there has been a lack of 
neuropathological verification of AD and thus they cannot be considered as reliable. Due to 
the limited number of subjects in study IV, no definitive conclusions can be drawn. 
Interestingly, two of the seven subjects with HS of unknown origin, or “pure HS” displayed 
 
 
EP.  The question of whether HS is actually the cause or consequence of seizures in temporal 
lobe EP still remains somewhat open. 
6.7 FUTURE ASPECTS 
First of all, the terminology on hippocampal lesions and especially HS should be harmonized 
in order to make future studies better comparable. The genetics of HS related to aging as well 
as in EP are currently being widely studied and it is clear that if one wishes to correlate the 
pathological findings to the clinical phenotype, then the terminology has to be unambiguous. 
Few post-mortem studies on elderly subjects with EP have been conducted; these would be 
valuable as the connections between AD and EP are not attracting more and more attention. 
MRI technology has become widely available and smaller lesions can now detected in vivo. 
One can predict that clinicopathological studies will help to clarify the role of microscopic 
hippocampal infarcts.  Thus it is necessary to understand better the histopathogical lesions, 
such as microinfarcts, in order to correlate the findings to the clinical symptoms.  
 
TDP43 was originally identified as the pathological protein in FTLD, but later studies, 
including the present works, have indicated that it is very common in the elderly and seen 
in association with many different disorders.  The role of TDP43 in the elderly needs to be 
investigated further as in the future it may be a potential therapeutic target. As far as is 
known, there have been no studies regarding the prevalence of EP in subjects with FTLD. It 
is very important to study the epidemiological factors in seizures in the elderly subjects 
suffering from neurodegenerative diseases, especially AD. Thus additional clinopathological 
studies are certainly merited to investigate the pathological substrate for EP in AD. It would 
be of great importance to clinically identify the subjects with HS-aging pathology e.g. 
perhaps these patients do not respond to the medications commonly used to treat AD. In 
addition, TDP43-pathology cannot be tested yet ante-mortem and it is would be important 
to develop methods to resolve this deficit, as they represent a distinct subgroup of patients.  
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7 Conclusions 
Based on these results, the following conclusions can be drawn: 
 
1. In a large unselected post mortem material, hippocampal lesions are seen in 18% of the 
cases. This includes different types of lesions ranging from small microinfarcts to HS and 
degeneration due to AD-pathology.  
 
2. Hippocampal infarcts are associated with large hemispheric brain infarcts, heart failure 
and overall increased cardiovascular morbidity.  
 
3. Hippocampal TDP43 pathology is common if there is an alteration seen in a conventionally 
stained section and the likelihood increases with neurodegenerative diseases such as AD i.e. 
it is particularly high when concomitant AD- and αS-pathology is present.  
 
4. Hipocampal alterations seen in autopsy practice can be divided into five types based on 
cell loss, changes in the neuropil, presence of ischemic lesions, and the presence of 
neurodegenerative lesions. Immunohistochemical staining should be used routinely to 
visualize neurodegenerative lesions and p62 is a useful screening antibody. The agreement 
rate regarding the designation of HS was highest for the type 4 lesions, which resembles the 
lesion originally described by Sommer. The use of the term HS should be restricted to specific 
types of pathology, and the underlying etiology should be specified (AD-related HS, FTD-
TDP-related HS etc. “HS lacking known neurodegenerative markers” should be reserved for 
cases of type 4 pathology lacking HPtau, TDP-43, fused in sarcoma (FUS) or αS lesions. The 
term “mesial temporal sclerosis” should best be restricted in routine and research pathology 
to cases associated with TLE.  
 
5. HS in the elderly may be associated with EP, but this finding will need to be verified in a 
larger material.  
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